WO2000076519A1 - Sulfonamide and sulfamide substituted imidazoquinolines - Google Patents

Sulfonamide and sulfamide substituted imidazoquinolines Download PDF

Info

Publication number
WO2000076519A1
WO2000076519A1 PCT/US2000/015722 US0015722W WO0076519A1 WO 2000076519 A1 WO2000076519 A1 WO 2000076519A1 US 0015722 W US0015722 W US 0015722W WO 0076519 A1 WO0076519 A1 WO 0076519A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
butyl
imidazo
quinolin
amino
Prior art date
Application number
PCT/US2000/015722
Other languages
French (fr)
Inventor
Stephen L. Crooks
Kyle J. Lindstrom
Bryon A. Merrill
Michael J. Rice
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001502852A priority Critical patent/JP4833466B2/en
Priority to MXPA01012547A priority patent/MXPA01012547A/en
Priority to EP00938211A priority patent/EP1198233B1/en
Priority to EEP200100669A priority patent/EE05074B1/en
Priority to IL14648600A priority patent/IL146486A0/en
Priority to DE60030126T priority patent/DE60030126T2/en
Priority to NZ515967A priority patent/NZ515967A/en
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Priority to CA2376305A priority patent/CA2376305C/en
Priority to BRPI0011433-2B1A priority patent/BR0011433B1/en
Priority to HU0201431A priority patent/HU229928B1/en
Priority to AU53284/00A priority patent/AU772179B2/en
Priority to PL352554A priority patent/PL211009B1/en
Priority to SK1792-2001A priority patent/SK286418B6/en
Priority to SI200030908T priority patent/SI1198233T1/en
Priority to UA2001128448A priority patent/UA73503C2/en
Publication of WO2000076519A1 publication Critical patent/WO2000076519A1/en
Priority to NO20015502A priority patent/NO320747B1/en
Priority to IL146486A priority patent/IL146486A/en
Priority to HR20010890A priority patent/HRP20010890B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063Periodont
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to imidazoquinoline compounds that have sulfonamide or sulfamide substitution at the 1 -position and to pharmaceutical compositions containing the compounds.
  • a further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases.
  • EP 894 797 discloses amide substituted imidazoquinoline compounds that are disclosed to be useful as immune response modifying compounds
  • WO 00/09506 discloses imidazoquinoline compounds that contain a sulfonamide substituent wherein the sulfonamide nitrogen is part of a saturated heterocyclic ring.
  • the compounds of Formula I are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune reponse when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
  • the invention further provides pharmaceutial compositions containing a therapeutic ally effective amount of a compound of Formula I and methods of inducing cytokine biosynthesis in an animal, treating a viral infection and/or treating a neoplastic disease in an animal by administering a effective amount of a compound of Formula I to the animal.
  • methods of synthesizing compounds of Formula I and intermediates useful in the synthesis of these compounds are provided.
  • Ri is -alkyl-NR,- SO 2 -X-R-i or -alkenyl-NR 3 - SO 2 -X-R 4 ;
  • R- t is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of: -alkyl;
  • R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
  • each R 3 is independently selected from the group consisting of hydrogen and C MO alkyl
  • R 5 is selected from the group consisting of hydrogen and C MO alkyl, or Rj and R 5 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring
  • n is 0 to 4 and each R present is independently selected from the group consisting of C O alkyl, C MO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
  • Imidazoquinolines of the invention can be prepared according to Reaction Scheme I where R, Ri, R 2 and n are as defined above.
  • step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula II is reacted with an amine of Formula R ⁇ NH 2 where Ri is as defined above to provide a 3- nitroquinolin-4-amine of Formula III.
  • the reaction can be carried out by adding amine to a solution of a compound of Formula II in a suitable solvent such as chloroform or dichloromethane and optionally heating.
  • a suitable solvent such as chloroform or dichloromethane
  • Many quinolines of Formula II are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein).
  • step (2) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula III is reduced to provide a quinoline-3,4-diamine of Formula IV.
  • the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon.
  • the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as isopropyl alcohol or toluene.
  • a quinoline-3,4-diamine of Formula IV is reacted with a carboxylic acid or an equivalent thereof to provide a lH-imidazo[4,5-c]quinoline of Formula V.
  • Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1 , 1 -dialkoxyalkyl alkanoates.
  • the carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula V.
  • triethyl orthoformate will provide a compound where R 2 is hydrogen and triethyl orthoacetate will provide a compound where R 2 is methyl.
  • the reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • step (4) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline of Formula V is oxidized to provide a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula VI using a conventional oxidizing agent that is capable of forming N-oxides.
  • Preferred reaction conditions involve reacting a solution of a compound of Formula V in chloroform with 3- chloroperoxybenzoic acid at ambient conditions.
  • step (5) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula VI is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula VII which is a subgenus of Formula I.
  • Step (5) involves (i) reacting a compound of Formula VI with an acylating agent and then (ii) reacting the product with an aminating agent.
  • Part (i) of step (5) involves reacting an N-oxide of Formula VI with an acylating agent.
  • Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. P-.r ⁇ -toluenesulfonyl chloride is most preferred.
  • Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent.
  • Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred.
  • the reaction is preferably carried out by dissolving the N-oxide of Formula VI in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then slowly adding the acylating agent.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (5) may be carried out by (i) reacting an N-oxide of Formula VI with an isocyanate and then (ii) hydrolyzing the resulting product.
  • Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group.
  • Preferred isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate.
  • the reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as chloroform or dichloromethane.
  • Part (ii) involves hydrolysis of the product from part (i).
  • the hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.
  • Reaction Scheme II an aminoalkyl substituted lH-imidazo[4,5-c]quinolin-4- amine of Formula VIII is reacted with a sulfonyl chloride of Formula IX to provide a compound of Formula X which is a subgenus of Formula I.
  • the reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine.
  • Many lH-imidazo[4,5-c]quinolin-4- amines of Formula VIII are known compounds, see for example US Patent 6,069,149 (Namba); others can be readily prepared using known synthetic methods.
  • Many sulfonyl chlorides of Formula IX are commercially available; others can be readily prepared using known synthetic methods.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • substituent contains a sulfonamide
  • Reaction Scheme III where R, R 2 , R 4 and n are as defined above and m is 1-20.
  • an aminoalkyl substituted lH-imidazo[4,5-c]quinolin-4- amine of Formula VIII is reacted with a sulfonic anhydride of Formula XI to provide a compound of Formula X which is a subgenus of Formula I.
  • the reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine. Alternatively, the reaction can be run at ambient temperature in acetonitrile.
  • Many sulfonic anhydrides of Formula XI are commercially available; others can be readily prepared using known synthetic methods.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Tertiary sulfonamides of the invention can be prepared according to Reaction Scheme IV where R, R 2 , R 3 , R 4 and n are as defined above and m is 1-20.
  • Reaction Scheme IV a lH-imidazo[4,5-c]quinolinyl sulfonamide of Formula X is reacted with a halide of Formula XII to provide a compound of Formula XIII which is a subgenus of Formula I.
  • the reaction can be carried out at ambient temperature by adding sodium hydride to a solution of a compound of Formula X in N,N-dimethylformamide and then adding the halide.
  • Many halides of Formula XII are commercially available; others can be readily prepared using known synthetic methods.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Rj contains a sulfamide group
  • Reaction Scheme V wherein R, R 2 , R 4 , R 5 and n are as defined above and m is 1-20.
  • step (1) of Reaction Scheme V an aminoalkyl substituted lH-imidazo[4,5- c]quinolin-4-amine of Formula VIII is reacted with sulfuryl chloride to generate in situ a sulfamoyl chloride of Formula XIV.
  • the reaction can be carried out by adding a solution of sulfuryl chloride in dichloromethane to a solution of a compound of Formula VIII in dichloromethane in the presence of one equivalent of 4-(dimethylamino)pyridine.
  • the reaction is preferably carried out at a reduced temperature (-78°C).
  • the reaction mixture can be allowed to warm to ambient temperature.
  • step (2) of Reaction Scheme V an amine of Formula R 5 R 4 N ⁇ is reacted with the sulfamoyl chloride of Formula XIV to provide a lH-imidazo[4,5-c]quinolinyl sulfamide of Formula XV which is a subgenus of Formula I.
  • the reaction can be carried out by adding a solution containing 2 equivalents of the amine and 2 equivalents of triethylamine in dichloromethane to the reaction mixture from step (1). The addition is preferably carried out at a reduced temperature (-78°C). After the addition is complete the reaction mixture can be allowed to warm to ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Tetrahydroimidazoquinolines of the invention can be prepared according to Reaction Scheme VI where R 2 , R 3 , R 4 , and R 5 are as defined above and m is 1-20.
  • step (1) of Reaction Scheme VI an aminoalkyl substituted lH-imidazo[4,5- c]quinolin-4-amine of Formula XVI is reduced to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XVII.
  • the reduction is carried out by suspending or dissolving the compound of Formula XVI in trifluoroacetic acid, adding a catalytic amount of platinum (IV) oxide, and then subjecting the mixture to hydrogen pressure.
  • the reaction can conveniently be carried out on a Parr apparatus.
  • the product or a salt thereof can be isolated using conventional methods.
  • step (2a) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of Formula XVIII which is a subgenus of Formula I.
  • R is hydrogen
  • the reaction can be carried out in one step according to the methods described in Reaction Schemes II and III above using a tetrahydroimidazoquinoline of Formula XVII in place of the imidazoquinoline of Formula VIII.
  • R 3 is other than hydrogen
  • the reaction can be carried out in two steps with step one being carried out according to the methods of Reaction Schemes II and III and step two being carried out according to the method of
  • Reaction IV using the tetrahydroimidazoquinoline analog of the imidazoquinoline.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (2b) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of
  • Tetrahydroimidazoquinolines of the invention can also be prepared according to Reaction Scheme VII where R, R 2 , R , R 4 , R and n are as defined above and m is 1-20.
  • step (1) of Reaction Scheme VII a 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolinyl tert-butylcarbamate of Formula XX is hydrolyzed to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XXI.
  • the reaction can be carried out dissolving the compound of Formula XX in a mixture of trifluoroacetic acid and acetonitrile and stirring at ambient temperature.
  • the compound of Formula XX can be combined with dilute hydrochloric acid and heated on a steam bath.
  • Tetrahydro-lH-imidazo[4,5-c]quinolinyl tert-butylcarbamates of Formula XX can be prepared using the synthetic route disclosed in U.S. Patent 5,352,784 (Nikolaides).
  • the product or a salt thereof can be isolated using conventional methods.
  • Some compounds of Formula I can be readily prepared from other compounds of Formula I.
  • compounds wherein the R substituent contains a chloroalkyl group can be reacted with an amine to provide an R 4 substituent substituted by a secondary or teriary amino group; compounds wherein the R substituent contains a nitro group can be reduced to provide a compound wherein the R 4 substituent contains a primary amine.
  • the terms "alkyl”, “alkenyl”, “alkynyl” and the prefix "-alk” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to
  • haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including groups wherein all of the available hydrogen atoms are replaced by halogen atoms. This is also true of groups that include the prefix "haloalk-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, tetrazolyl, imidazo, pyrazolo, thiazolo, oxazolo, and the like.
  • Heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N).
  • exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, and the like.
  • substituted cycloalkyl indicates that the rings or ring systems in question are further substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy (e.g., trifluoromethoxy), nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl, alkanoyloxy, alkanoylthio, and in the case of cycloalkyl and heterocyclyl, oxo.
  • substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloal
  • bonds are represented by dashed lines. These lines mean that the bonds represented by the dashed line can be present or absent. Accordingly, compounds of Formula I can be either imidazoquinoline compounds or tetrahydroimidazoquinoline compounds.
  • the invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers such as diastereomers and enantiomers, salts, solvates, polymorphs, and the like.
  • compositions and Biological Activity contain a therapeutically effective amount of a compound of Formula I in combination with a pharmaceutically acceptable carrier.
  • a therapeutically effective amount means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity and/or antiviral activity.
  • a therapeutically effective amount means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity and/or antiviral activity.
  • the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound as well as the nature of the carrier and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg of the compound to the subject.
  • Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmu
  • the compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
  • Cytokines that may be induced by the administration of compounds according to the invention generally include interferon- ⁇ (IFN- ⁇ ) and tumor necrosis factor- ⁇ (TNF- ⁇ ) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN- ⁇ , TNF- ⁇ , IL-1, 6, 10 and 12, and a variety of other cytokines. Among other effects, cytokines inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors.
  • IFN- ⁇ interferon- ⁇
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IL-1 interleukins
  • the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction.
  • the compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
  • Compounds of the invention also have an effect on the acquired immune response.
  • the production of the T helper type 1 (Thl) cytokine IFN- ⁇ is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds.
  • This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired.
  • the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, and allergic rhinitis; and systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
  • atopic diseases e.g., atopic dermatitis, asthma, allergy, and allergic rhinitis
  • systemic lupus erythematosis e.g., atopic dermatitis, asthma, allergy, and allergic rhinitis
  • systemic lupus erythematosis e.g., as a vaccine adjuvant for cell mediated immunity
  • possibly as a treatment for recurrent fungal diseases and chlamydia e.g., atopic dermatitis, asthma, allergy, and allergic rhinitis
  • the immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN- ⁇ and/or TNF- ⁇ , the compounds are particularly useful in the treatment of viral diseases and tumors.
  • This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum; HIV;
  • CMV CMV
  • VZV intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
  • Candida aspergillus, and cryptococcal meningitis
  • neoplastic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
  • parasitic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
  • parasitic diseases e.g.
  • Additional diseases or conditions that can be treated using the compounds of the invention include eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; and to enhance or stimulate the healing of wounds, including chronic wounds.
  • the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of Formula I to the animal.
  • An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN- ⁇ , TNF- ⁇ , IL-1, 6, 10 and 12 that is increased over the background level of such cytokines.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of about lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg.
  • the invention also provides a method of treating a viral infection in an animal, and a method of treating a neoplastic disease in an animal, comprising administering an effective amount of a compound of Formula I to the animal.
  • An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg.
  • An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about lOOng/kg to about 50mg/kg, preferably about 1 O ⁇ g/kg to about 5mg/kg.
  • 2-Thiophenesulfonyl chloride (0.3 g in 10 ml dichloromethane, 1.6 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5- c]quinoline-4-amine (0.5 g, 1.6 mmol), dichloromethane (40 ml), and pyridine (0.8 ml). The reaction was maintained at room temperature for a few hours and then an additional portion of 2-thiophenesulfonyl chloride (0.1 g, 0.6 mmol) was added. The reaction was maintained overnight and then concentrated in vacuo.
  • ⁇ -Toluenesulfonyl chloride (0.5 g in 10 ml dichloromethane, 2.7 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinoline-4- amine (0.75 g, 2.4 mmol), dichloromethane (115 ml), and pyridine (1 ml). The reaction was maintained at room temperature for 4 hours and then concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethane ⁇ methanol, Rf 0.16). The fractions containing product were combined and washed with saturated aqueous bicarbonate.
  • Benzenesulfonyl chloride (0.45 ml in 10 ml dichloromethane, 3.5 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5- c]quinoline-4-amine (1.0 g, 3.2 mmol), dichloromethane (140 ml), and pyridine (0.8 ml). The reaction was maintained at room temperature for four hours and then concentrated in vacuo.
  • Methanesulfonic anhydride (0.6 g, 3.4 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinoline-4-amine (1.0 g, 3.2 mmol) and acetonitrile (200 ml). A precipitate formed within a few minutes. The solvent was removed in vacuo and the residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The fractions were separated and the organic fraction was dried (MgSO ), filtered and concentrated to yield the crude product as a white solid.
  • Methanesulfonic anhydride (0.19 g, 1.1 mmol) was added to a stirring solution of l-(4-aminobutyl)-2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-4-amine (0.4 g, 1.07 mmol), dichloromethane (75 ml) and acetonitrile (100 ml). The reaction was maintained at room temperature for 60 hours. The solvent was removed in vacuo and the residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethane ⁇ methanol).
  • the semi-prep hplc fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized.
  • the solid was dissolved in ca. 3 mL of 2: 1 dichloromethane-methanol and shaken with ca. 80 mg (300 ⁇ mol) of diisopropylaminomethyl-polystyrene resin (Argonaut PS-DIEA, 3.86 mmol/g) for ⁇ 2 h to liberate the free amine, and then filtered and dried in vacuo to give the product as a solid.
  • MS (APCI) m/ 376.16 (M+ ⁇ ).
  • Triethylamine (7.26 g, 71.7 mmol) was added to a solution of the material from Part A in ethanol (200 mL) and heated at reflux for 2 days. The reaction mixture was concentrated to provide an orange syrup. HPLC mass spec analysis showed that the syrup contained the desired product and starting material. The syrup was taken up in dichloromethane (100 mL) and then cooled in an ice bath. Triethylamine (5 mL) and benzoyl chloride (1.9 mL) were added. The reaction mixture was maintained at ambient temperature for 2 days at which time analysis by HPLC indicated that the reaction was not complete. The reaction mixture was concentrated under vacuum. The residue was taken up in isopropyl alcohol (150 mL).
  • Triethylamine (5 mL) was added and the reaction mixture was heated at reflux overnight. The reaction mixture was concentrated under vacuum. The residue was purified by flash chromatography (silica gel; eluting with 10% methanol in dichloromethane). The fractions containing product were combined and concentrated under vacuum. The residue was recrystallized from acetonitrile to provide 6.7 g of tert-butyl N-[4-(2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]carbamate as a solid, m.p. 158-159°C.
  • Part E The material from Part D was dissolved in methanol (15 mL) and 1 N hydrochloric acid (100 mL) and then heated at reflux for 2 hours. The reaction mixture was concentrated under vacuum to a volume of about 50 mL. Addition of concentrated ammonium hydroxide to pH 12 did not produce a precipitate. The pH was adjusted to 7 with 1 N hydrochloric acid. The mixture was extracted with dichloromethane and then with ethyl acetate.
  • the semi- prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
  • the reaction mixture was left on the shaker for an additional hour and then it was put on a sonicator for about 0.5 hours.
  • the reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the semi- prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide. Examples 41 - 52
  • the semi-prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
  • the vial was placed on a shaker for about 6 hours.
  • the reaction mixture was allowed to stand at ambient temperature overnight and was analyzed by LC/MS to confirm the formation of the desired product.
  • the semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
  • This compound was prepared using the method of Examples 54 - 71 above except that 1.1 eq of methanesulfonic anhydride was used in place of the sulfonyl chloride.
  • the lH-imidazo[4,5-c]quinolin-4-amine (50 mg) was placed in a 2 dram (7.4 mL) vial. Diisopropylethylamine (1.2 eq) in dichloromethane (-1 mL) was added. A solution containing the sulfonyl chloride (1.1 eq) in dichloromethane ( ⁇ 1 mL) was added. The vial was placed on a shaker for about 2 - 16 (usually 2) hours at ambient temperature. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the semi -prep ⁇ PLC fractions were analyzed by LC- APCI MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
  • the tetrahydroquinoline amine starting materials were prepared as follows. A catalytic amount of platinum (IV) oxide was added to a solution of l-(4- aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (2.2 g, 7.06 mmol) in trifluoroacetic acid (200 mL). The reaction mixture was hydrogenated at 50 psi (3.44 X 10 Pa) on a Parr apparatus for 6 days.. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum. The residue was combined with 1 N hydrochloric acid (100 mL) and heated on a steam bath for 2 hours.
  • platinum (IV) oxide was added to a solution of l-(4- aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (2.2 g, 7.06 mmol) in trifluoroacetic acid (200 mL).
  • the reaction mixture was hydrogen
  • a catalytic amount of platinum (IV) oxide was added to a solution of l-(4- aminobutyl)-2-methoxyethyl-lH-imidazo[4,5-c]quinolin-4-amine (7.7 g, 24.5 mmol) in trifluoroacetic acid (250 mL).
  • the reaction mixture was hydrogenated at 50 psi (3.44 X 10 5 Pa) on a Parr apparatus. The progress of the reaction was monitored by LC/MS. Additional catalyst was added 7, 11, and 17 days after the start of the reaction. After 25 days the reaction was complete.
  • the reaction mixture was filtered through a layer of Celite® filter aid to remove the catalyst and the filtrate was concentrated under vacuum.
  • This compound was prepare using the method of Examples 202 - 213 above except that methanesulfonic anhydride was used in place of the sulfonyl chloride.
  • the semi- prep HPLC fractions were analyzed by LC-APCI MS and the appropriate fractions were combined and lyophilized.
  • the lyophilized material was purified a second time by semi- preparative HPLC using the same conditions except that the gradient elution from 5-95% B was run for 60 minutes instead of 10 minutes.
  • the semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired amide.
  • This compound was prepared using the general method of Example 215 above, except that trifluoromethanesulfonic anhydride was used in place of the sulfonyl chloride in Part A.
  • Examples 217 - 221 The examples in the table below were prepare using the following general method.
  • the lH-imidazo[4,5-c]quinolin-4-amine or the 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolin-4-amine (50 mg) was placed in a 2 dram (7.4 mL) vial.
  • Dichloromethane (2 mL) and diisopropylethylamine (1.2 eq) were added.
  • Dimethylsulfamoyl chloride (1.1 eq) was added.
  • the vial was placed on a shaker for about 2 - 4 hours at ambient temperature.
  • the reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the semi-prep HPLC fractions were analyzed by LC- APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfamide.
  • Examples 222 - 228 The examples in the table below were prepared according to the synthetic method shown in Reaction Scheme V above. l-(4-Aminobutyl)-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine (50 mg) was placed in a 2 dram (7.4 mL) vial. 4-(Dimethylamino)pyridine (19 mg, 1.0 eq) and dichloromethane (800 ⁇ L) were added. The vial was sealed and cooled to -78°C in a dry ice/acetone bath. Sulfuryl chloride (186 ⁇ L of 1 M in dichloromethane) was added.
  • the vial was put on a shaker for about 30 minutes and then cooled back down to -78°C.
  • a separate vial was charged with the amine of formula R 4 R ⁇ N ⁇ (2.0 eq), triethylamine (2.0 eq) and dichloromethane (1 mL) and cooled to -78°C.
  • the amine/triethylamine solution was added to the first vial.
  • the vial was placed on a shaker at ambient temperature for about 1 hour.
  • the reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfamide.
  • Examples 229 - 231 The examples in the table below were prepared using the method of Examples 222 - 228 above except that the amine of formula R 4 R NH was reacted with the sulfuryl chloride to provide the sulfamoyl chloride intermediate which was then reacted with 2.0 eq of l-(4-aminobutyl)-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine.
  • PBMCs Peripheral blood mononuclear cells
  • Histopaque®-1077 Sigma Chemicals, St. Louis, MO.
  • the PBMCs are suspended at 3-4 x 10 6 cells/mL in RPMI
  • PBMC 1640 medium containing 10 % fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin solution (RPMI complete).
  • RPMI complete 1640 medium containing 10 % fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin solution.
  • the PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound.
  • the compounds are solubilized in dimethyl sulfoxide (DMSO).
  • DMSO concentration should not exceed a final concentration of 1 % for addition to the culture wells.
  • test compound is added at 60 ⁇ M to the first well containing RPMI complete and serial (three fold or ten fold) dilutions are made.
  • the PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range.
  • the final concentration of PBMC suspension is 1.5-2 X 10 6 cells/mL.
  • the plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37°C in a 5% carbon dioxide atmosphere.
  • Interferon ( ⁇ ) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ.
  • Tumor necrosis factor ( ⁇ ) (TNF)concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA.
  • the table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound.
  • a "**” indicates that no induction was seen at any of the tested concentrations (0.12, 0.37, 1.1 1, 3.33, 10 and 30 ⁇ M).
  • a "***” indicates that no induction was seen at any of the tested concentrations (0.0001, 0.001, 0.01, 0.1, 1 and 10 ⁇ M).

Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Description

Sulfonamide and Sulfamide Substituted Imidazoquinolines
Field of the Invention
This invention relates to imidazoquinoline compounds that have sulfonamide or sulfamide substitution at the 1 -position and to pharmaceutical compositions containing the compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases.
Background of the Invention
The first reliable report on the lH-imidazo[4,5-c]quinoline ring system, Backman et al., J. Ore. Chem. 15, 1278-1284 (1950) describes the synthesis of l-(6-methoxy-8- quinolinyl)-2-methyl-lH-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted lH-imidazo[4,5-c] quinolines were reported. For example, Jain et al., J. Med. Chem. 1 1, pp. 87-92 (1968), synthesized the compound l-[2-(4-piperidyl)ethyl]-lH-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J, Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5- c]quinolines.
Certain lH-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, ter alia, U.S. Patent Nos. 4,689,338; 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference.
There continues to be interest in the imidazoquinoline ring system, as seen for example in WO 98/30562, EP 894 797 and WO 00/09506. EP 894 797 discloses amide substituted imidazoquinoline compounds that are disclosed to be useful as immune response modifying compounds, while WO 00/09506 discloses imidazoquinoline compounds that contain a sulfonamide substituent wherein the sulfonamide nitrogen is part of a saturated heterocyclic ring. Despite these efforts, however, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.
Summary of the Invention
We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides compounds of Formula I:
Figure imgf000003_0001
(I) wherein R, R\ and R are as defined herein. The compounds of Formula I are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune reponse when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response. The invention further provides pharmaceutial compositions containing a therapeutic ally effective amount of a compound of Formula I and methods of inducing cytokine biosynthesis in an animal, treating a viral infection and/or treating a neoplastic disease in an animal by administering a effective amount of a compound of Formula I to the animal. In addition, methods of synthesizing compounds of Formula I and intermediates useful in the synthesis of these compounds are provided.
Detailed Description of the Invention
As mentioned earlier, the invention provides compounds of Formula I:
Figure imgf000004_0001
(I) wherein
Ri is -alkyl-NR,- SO2 -X-R-i or -alkenyl-NR3- SO2 -X-R4 ;
Figure imgf000004_0002
R-t is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of: -alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; -substituted aryl;
-substituted heteroaryl;
-substituted heterocyclyl;
-O-alkyl;
-O-(alkyl)0-i-aryl; -O-(alkyl)o 1 -substituted aryl;
-O-(alkyl)o- 1 -heteroaryl ;
-O-(alkyl)o 1 -substituted heteroaryl;
-O-(alkyl)o-ι-heterocyclyl;
-O-(alkyl)o- 1 -substituted heterocyclyl ; -COOH;
-CO-O-alkyl; -CO-alkyl;
-S(O)o-2 -alkyl;
-S(O)0-2-(alkyl)o-ι-aryl;
-S(O)o-2 -(alkyl)o-ι -substituted aryl;
-S(O)o-2-(alkyl)o-i -heteroaryl;
-S(O)o-2 -(alkyl)o-ι -substituted heteroaryl;
-S (O)o-2 -(alkyl)o- 1 -heterocyclyl ;
-S(O)o-2-(alkyl)o-ι -substituted heterocyclyl;
-(alkyl)0-ι-NR R ;
-(alkyl)o _-,-NR3-CO-O-alkyl;
-(alkyl)o _-,-NR3-CO-alkyl;
-(alkyl)o .-,-NR3-CO-aryl;
-(alkyl)o --ι-NR3-CO-substituted aryl;
-(alkyl)o -- 1 -NR3-CO-heteroaryl ;
-(alkyl)o -- 1 -NR3-CO-substi tuted heteroaryl ;
-N3;
-halogen;
-haloalkyl;
-haloalkoxy;
-CO-haloalkoxy;
-NO2;
-CN;
-OH;
-SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo;
R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
-substituted aryl; -heteroaryl; -substituted heteroaryl;
- alkyl -O-alkyl;
- alkyl-O- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH; -halogen;
-N(R3)2; -CO-N(R3)2; -CO-Ci-io alkyl;
-CO-O-Cι_io alkyl; -N3; -aryl;
-substituted aryl; -heteroaryl;
-substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl; -CO-aryl; -CO-(substituted aryl);
-CO-heteroaryl; and -CO-(substituted heteroaryl); each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; R5 is selected from the group consisting of hydrogen and CMO alkyl, or Rj and R5 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; n is 0 to 4 and each R present is independently selected from the group consisting of C O alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof. Preparation of the Compounds
Imidazoquinolines of the invention can be prepared according to Reaction Scheme I where R, Ri, R2 and n are as defined above.
In step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula II is reacted with an amine of Formula RιNH2 where Ri is as defined above to provide a 3- nitroquinolin-4-amine of Formula III. The reaction can be carried out by adding amine to a solution of a compound of Formula II in a suitable solvent such as chloroform or dichloromethane and optionally heating. Many quinolines of Formula II are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein). In step (2) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula III is reduced to provide a quinoline-3,4-diamine of Formula IV. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as isopropyl alcohol or toluene. In step (3) of Reaction Scheme I a quinoline-3,4-diamine of Formula IV is reacted with a carboxylic acid or an equivalent thereof to provide a lH-imidazo[4,5-c]quinoline of Formula V. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1 , 1 -dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula V. For example, triethyl orthoformate will provide a compound where R2 is hydrogen and triethyl orthoacetate will provide a compound where R2 is methyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
In step (4) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline of Formula V is oxidized to provide a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula VI using a conventional oxidizing agent that is capable of forming N-oxides. Preferred reaction conditions involve reacting a solution of a compound of Formula V in chloroform with 3- chloroperoxybenzoic acid at ambient conditions.
In step (5) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula VI is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula VII which is a subgenus of Formula I. Step (5) involves (i) reacting a compound of Formula VI with an acylating agent and then (ii) reacting the product with an aminating agent. Part (i) of step (5) involves reacting an N-oxide of Formula VI with an acylating agent. Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. P-.rø-toluenesulfonyl chloride is most preferred. Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula VI in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then slowly adding the acylating agent. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Alternatively, step (5) may be carried out by (i) reacting an N-oxide of Formula VI with an isocyanate and then (ii) hydrolyzing the resulting product. Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group. Preferred isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate. The reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as chloroform or dichloromethane. Part (ii) involves hydrolysis of the product from part (i). The hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.
Reaction Scheme I
Figure imgf000009_0001
(3)
Figure imgf000009_0002
VII VI V
Compounds of the invention where the R( substituent contains a sulfonamide can also be prepared according to Reaction Scheme II where R, R2, R and n are as defined above and m is 1-20.
In Reaction Scheme II an aminoalkyl substituted lH-imidazo[4,5-c]quinolin-4- amine of Formula VIII is reacted with a sulfonyl chloride of Formula IX to provide a compound of Formula X which is a subgenus of Formula I. The reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine. Many lH-imidazo[4,5-c]quinolin-4- amines of Formula VIII are known compounds, see for example US Patent 6,069,149 (Namba); others can be readily prepared using known synthetic methods. Many sulfonyl chlorides of Formula IX are commercially available; others can be readily prepared using known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme II
Figure imgf000010_0001
Compounds of the invention where the R| substituent contains a sulfonamide can also be prepared according to Reaction Scheme III where R, R2, R4 and n are as defined above and m is 1-20.
In Reaction Scheme III an aminoalkyl substituted lH-imidazo[4,5-c]quinolin-4- amine of Formula VIII is reacted with a sulfonic anhydride of Formula XI to provide a compound of Formula X which is a subgenus of Formula I. The reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine. Alternatively, the reaction can be run at ambient temperature in acetonitrile. Many sulfonic anhydrides of Formula XI are commercially available; others can be readily prepared using known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme III
Figure imgf000010_0002
Tertiary sulfonamides of the invention can be prepared according to Reaction Scheme IV where R, R2, R3, R4 and n are as defined above and m is 1-20.
In Reaction Scheme IV a lH-imidazo[4,5-c]quinolinyl sulfonamide of Formula X is reacted with a halide of Formula XII to provide a compound of Formula XIII which is a subgenus of Formula I. The reaction can be carried out at ambient temperature by adding sodium hydride to a solution of a compound of Formula X in N,N-dimethylformamide and then adding the halide. Many halides of Formula XII are commercially available; others can be readily prepared using known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme IV
Figure imgf000011_0001
Compounds of the invention where Rj contains a sulfamide group can be prepared according to Reaction Scheme V wherein R, R2, R4, R5 and n are as defined above and m is 1-20.
In step (1) of Reaction Scheme V an aminoalkyl substituted lH-imidazo[4,5- c]quinolin-4-amine of Formula VIII is reacted with sulfuryl chloride to generate in situ a sulfamoyl chloride of Formula XIV. The reaction can be carried out by adding a solution of sulfuryl chloride in dichloromethane to a solution of a compound of Formula VIII in dichloromethane in the presence of one equivalent of 4-(dimethylamino)pyridine. The reaction is preferably carried out at a reduced temperature (-78°C). Optionally, after the addition is complete the reaction mixture can be allowed to warm to ambient temperature. In step (2) of Reaction Scheme V an amine of Formula R5R4NΗ is reacted with the sulfamoyl chloride of Formula XIV to provide a lH-imidazo[4,5-c]quinolinyl sulfamide of Formula XV which is a subgenus of Formula I. The reaction can be carried out by adding a solution containing 2 equivalents of the amine and 2 equivalents of triethylamine in dichloromethane to the reaction mixture from step (1). The addition is preferably carried out at a reduced temperature (-78°C). After the addition is complete the reaction mixture can be allowed to warm to ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme V
Figure imgf000012_0001
Tetrahydroimidazoquinolines of the invention can be prepared according to Reaction Scheme VI where R2, R3, R4, and R5 are as defined above and m is 1-20.
In step (1) of Reaction Scheme VI an aminoalkyl substituted lH-imidazo[4,5- c]quinolin-4-amine of Formula XVI is reduced to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XVII. Preferably the reduction is carried out by suspending or dissolving the compound of Formula XVI in trifluoroacetic acid, adding a catalytic amount of platinum (IV) oxide, and then subjecting the mixture to hydrogen pressure. The reaction can conveniently be carried out on a Parr apparatus. The product or a salt thereof can be isolated using conventional methods.
In step (2a) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of Formula XVIII which is a subgenus of Formula I. When R is hydrogen, the reaction can be carried out in one step according to the methods described in Reaction Schemes II and III above using a tetrahydroimidazoquinoline of Formula XVII in place of the imidazoquinoline of Formula VIII. When R3 is other than hydrogen, the reaction can be carried out in two steps with step one being carried out according to the methods of Reaction Schemes II and III and step two being carried out according to the method of
Reaction IV using the tetrahydroimidazoquinoline analog of the imidazoquinoline. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (2b) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of
Formula XIX which is a subgenus of Formula I. The reaction can be carried out according to the method described in Reaction Scheme V using a tetrahydroimidazoquinoline of Formula XVII in place of the imidazoquinoline of Formula VIII. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme VI
Figure imgf000013_0001
Tetrahydroimidazoquinolines of the invention can also be prepared according to Reaction Scheme VII where R, R2, R , R4, R and n are as defined above and m is 1-20. In step (1) of Reaction Scheme VII a 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolinyl tert-butylcarbamate of Formula XX is hydrolyzed to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XXI. The reaction can be carried out dissolving the compound of Formula XX in a mixture of trifluoroacetic acid and acetonitrile and stirring at ambient temperature. Alternatively, the compound of Formula XX can be combined with dilute hydrochloric acid and heated on a steam bath. Tetrahydro-lH-imidazo[4,5-c]quinolinyl tert-butylcarbamates of Formula XX can be prepared using the synthetic route disclosed in U.S. Patent 5,352,784 (Nikolaides). The product or a salt thereof can be isolated using conventional methods.
Steps (2a) and (2b) can be carried out in the same manner as in Reaction Scheme VI. Reaction Scheme VII
Figure imgf000014_0001
Some compounds of Formula I can be readily prepared from other compounds of Formula I. For example, compounds wherein the R substituent contains a chloroalkyl group can be reacted with an amine to provide an R4 substituent substituted by a secondary or teriary amino group; compounds wherein the R substituent contains a nitro group can be reduced to provide a compound wherein the R4 substituent contains a primary amine. As used herein, the terms "alkyl", "alkenyl", "alkynyl" and the prefix "-alk" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to
20 carbon atoms, with alkenyl and alkynyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl and adamantyl. The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including groups wherein all of the available hydrogen atoms are replaced by halogen atoms. This is also true of groups that include the prefix "haloalk-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, tetrazolyl, imidazo, pyrazolo, thiazolo, oxazolo, and the like.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, and the like.
Unless otherwise specified, the terms "substituted cycloalkyl", "substituted aryl", "substituted heteroaryl" and "substituted heterocyclyl" indicate that the rings or ring systems in question are further substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy (e.g., trifluoromethoxy), nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl, alkanoyloxy, alkanoylthio, and in the case of cycloalkyl and heterocyclyl, oxo.
In structural formulas representing compounds of the invention certain bonds are represented by dashed lines. These lines mean that the bonds represented by the dashed line can be present or absent. Accordingly, compounds of Formula I can be either imidazoquinoline compounds or tetrahydroimidazoquinoline compounds. The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers such as diastereomers and enantiomers, salts, solvates, polymorphs, and the like.
Pharmaceutical Compositions and Biological Activity Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of Formula I in combination with a pharmaceutically acceptable carrier.
As used herein, the term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound as well as the nature of the carrier and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
Cytokines that may be induced by the administration of compounds according to the invention generally include interferon-α (IFN-α) and tumor necrosis factor-α (TNF-α) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN-α, TNF-α, IL-1, 6, 10 and 12, and a variety of other cytokines. Among other effects, cytokines inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors.
In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
Compounds of the invention also have an effect on the acquired immune response. For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine IFN-γ is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of Formula la to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, and allergic rhinitis; and systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-α and/or TNF-α, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum; HIV;
CMV; VZV; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g. Candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g. pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, leishmaniasis; and bacterial infections, e.g., tuberculosis, mycobacterium avium. Additional diseases or conditions that can be treated using the compounds of the invention include eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; and to enhance or stimulate the healing of wounds, including chronic wounds.
Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of Formula I to the animal. An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-α, TNF-α, IL-1, 6, 10 and 12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg. The invention also provides a method of treating a viral infection in an animal, and a method of treating a neoplastic disease in an animal, comprising administering an effective amount of a compound of Formula I to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about lOOng/kg to about 50mg/kg, preferably about 1 Oμg/kg to about 5mg/kg.
The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
Example 1 N'-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
5-(dimethylamino)- 1 -naphthalenesulfonamide
Figure imgf000018_0001
5-Dimethylamino-l-naphthalenesulfonyl chloride (1.82 g, 6.74 mmol) was added to a mixture of N,N-diisopropylethylamine (1.23 mL, 7.06 mmol), dichloromethane (15 mL) and l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.42 mmol). The reaction mixture was allowed to stir at ambient temperature overnight. Methanol was added to the reaction mixture until a clear solution was obtained. Silica gel was added to the reaction mixture and then the solvents were removed. The silica gel was placed in a column and then eluted with chloroform in a stepwise gradient to 9: 1 chloroforrmmethanol. The resulting product was recrystallized from N,N- dimethylformamide and deionized water to provide 2.5 g of N1-[4-(4-amino-2-butyl-lH- imidazo[4,5-c]quinolin- 1 -yl)butyl]-5-(dimethylamino)- 1 -naphthalenesulfonamide as a yellow crystalline solid, m.p. 223 -224°C. Analysis: Calculated for C3oH 6N6O2S: %C, 66.15; H, 6.66; %N, 15.43; Found: %C, 66.36; %H, 6.34; %N, 15.23.
Example 2 N'-[4-(4- Amino- lH-imidazo[4,5-c]quinolin-l-yl)butyl]- 5-(dimethylamino)- 1 -naphthalenesulfonamide
Figure imgf000019_0001
A suspension of l-(4-aminobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (0.5 g, 2.0 mmol) in pyridine (250 mL) was warmed to 60°C to dissolve the amine. The solution was allowed to cool to about 30°C and then 5-dimethylamino-l-naphthalenesulfonyl chloride
(0.5 g, 1.8 mmol) was slowly added. After 1 hour 0.3 g of 5-dimethylamino-l- naphthalenesulfonyl chloride was added. The reaction mixture was warmed to 60°C and maintained at that temperature overnight. The reaction mixture was concentrated under vacuum. The residue was recrystallized from propyl acetate to provide N'-[4-(4-amino- lH-imidazo[4,5-c]quinolin-l-yl)butyl]-5-(dimethylamino)-l -naphthalenesulfonamide as a solid, m.p. 200-201°C.
Example 3
N2-[4-(4-Amino-2-butyl-l HH--iimmiiddaazzoo[['4,5-c]quinolin-l-yl)butyl]-
2-thiophenesulfonamide
Figure imgf000020_0001
2-Thiophenesulfonyl chloride (0.3 g in 10 ml dichloromethane, 1.6 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5- c]quinoline-4-amine (0.5 g, 1.6 mmol), dichloromethane (40 ml), and pyridine (0.8 ml). The reaction was maintained at room temperature for a few hours and then an additional portion of 2-thiophenesulfonyl chloride (0.1 g, 0.6 mmol) was added. The reaction was maintained overnight and then concentrated in vacuo. The resulting residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethane\methanol) and the fractions containing product were washed with saturated aqueous sodium bicarbonate. The organic layer was dried (MgSO ), filtered, and concentrated to provide 0.2 g of N2-[4-
(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-2-thiophenesulfonamide as an off white powder, m.p. 137.5-141.5 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.00 (d, J=8.0 Hz, IH), 7.89 (dd, J=5.0, 1.3 Hz, IH), 7.83 (broad s, IH), 7.61 (dd, J=8.3, 1.1 Hz, IH), 7.54 (dd, J=3.7, 1.3 Hz, IH), 7.42 (t, J=7.2 Hz, IH), 7.25 (m, IH), 7.15 (m, IH), 6.44 (broad s, 2H), 4.47 (t, J=7.4 Hz, 2H), 2.87 (m, 4H), 1.80 (m, 4H), 1.58-1.38 (m, 4H), 0.96
(t, J=7.4 Hz, 3H); IR (KBr) 3467, 3361, 3167, 3091, 2957, 2933, 2870, 1644, 1617, 1585, 1533, 1478, 1405, 1336, 1154, 1095, 1014, 854, 761, 733 cm"1; MS (El) m/e 457.1606 (457.1606 calcd for C22H27N5O2S2); Anal calcd for C22H27N5O2S2: C, 57.74; H, 5.95; N, 15.30. Found: C, 57.50; H, 5.98; N, 15.15. Example 4
N-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl] phenylmethanesulfonamide
Figure imgf000021_0001
α-Toluenesulfonyl chloride (0.5 g in 10 ml dichloromethane, 2.7 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinoline-4- amine (0.75 g, 2.4 mmol), dichloromethane (115 ml), and pyridine (1 ml). The reaction was maintained at room temperature for 4 hours and then concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethane\methanol, Rf 0.16). The fractions containing product were combined and washed with saturated aqueous bicarbonate. The organic layer was dried (MgSO4), filtered, and concentrated. A final recrystallization from dichloromethane\diethyl ether provided 0.65 g of N-[4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l- yl)butyl]phenylmethanesulfonamide as a white crystalline solid, m.p. 197.0-199.5 °C. Η
NMR (300 MHz, DMSO-d6) δ 8.02 (d, J=7.6 Hz, IH), 7.62 (dd, J=8.3, 1.1 Hz, IH), 7.42 (dt, J=7.5, 1.1 Hz, IH), 7.35-7.23 (m, 7H), 7.12 (t, J=5.4 Hz, IH), 6.46 (broad s, 2H), 4.49 (t, J=7.5 Hz, 2H), 4.29 (s, 2H), 2.91 (m, 4H), 1.83-1.42 (m, 8H), 0.96 (t, J=7.4 Hz, 3H); IR (KBr) 3460, 3293, 3226, 3158, 2955, 2931, 2867, 1632, 1586, 1534, 1482, 1437, 1389, 1331, 1152, 1094, 752, 700 cm"1; MS (El) m/e 465.2204 (465.2198 calcd for
C25H3ιN5O2S); Anal calcd for C25H3,N5O2S: C, 64.49; H, 6.71; N, 15.04. Found: C, 64.15; H, 6.71; N, 15.00. Example 5
N'-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
1 -benzenesulfonamide
Figure imgf000022_0001
Benzenesulfonyl chloride (0.45 ml in 10 ml dichloromethane, 3.5 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5- c]quinoline-4-amine (1.0 g, 3.2 mmol), dichloromethane (140 ml), and pyridine (0.8 ml). The reaction was maintained at room temperature for four hours and then concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethane\methanol, Rf 0.28) followed by recrystallization from dichloromethane\diethyl ether to provide 1.14 g of N'-[4-(4-amino-2-butyl-lH- imidazo[4,5-c]quinolin-l-yl)butyl]-l -benzenesulfonamide as a white powder, m.p. 75.5- 79.0 °C. Η NMR (500 MHz, DMSO-d6) δ 7.99 (d, J=7.7 Hz, IH), 7.76 (d, J=7.2, 2H), 7.63-7.53 (m, 5H), 7.42 (m, IH), 7.25 (m, IH), 6.43 (broad s, 2H), 4.45 (t, J=7.6 Hz, 2H),
2.87 (t, J=7.7 Hz, 2H), 2.78 (m, 2H), 1.79 (m, 4H), 1.55-1.40 (m, 4H), 0.95 (t, J=7.4 Hz, 3H); MS (El) m/e 451.2036 (451.2042 calcd for C2 H29N5O2S); Anal calcd for C2 H29N5O2S: C, 63.83; H, 6.47; N, 15.51. Found: C, 63.89; H, 6.42; N, 15.30.
Example 6
N-[4-(4-Amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl] methanesulfonamide
Figure imgf000023_0001
Methanesulfonic anhydride (0.6 g, 3.4 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinoline-4-amine (1.0 g, 3.2 mmol) and acetonitrile (200 ml). A precipitate formed within a few minutes. The solvent was removed in vacuo and the residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The fractions were separated and the organic fraction was dried (MgSO ), filtered and concentrated to yield the crude product as a white solid. Recrystallization from methyl acetate provided N-[4-(4-amino-2-butyl-lH- imidazo[4,5-c]quinolin-l-yl)butyl]methanesulfonamide as a white crystalline solid, m.p. 195.1-196.0 °C. Η NMR (300 MHz, DMSO-d6) δ 8.04 (d, J=7.4 Hz, IH), 7.61 (dd, J=8.3, 1.2 Hz, IH), 7.50 (dt, J=7.5, 1.1 Hz, IH), 7.26 (dt, J=7.5, 1.2 Hz, IH), 6.99 (t, J=5.7
Hz, IH), 6.44 (broad s, 2H), 4.52 (t, J=7.5 Hz, 2H), 3.02-2.86 (m, 7H), 1.82 (m, 4H), 1.62 (m, 2H), 1.46 (q, J=7.4 Hz, 2H), 0.96 (t, J=7.4 Hz, 3H); IR (KBr) 3348, 3299, 3152, 2952, 2931, 2869, 1642, 1584, 1530, 1480, 1323, 1155, 1 142, 1094, 982, 765 cm"1; MS (El) m/e 389.1889 (389.1885 calcd for Cι9H27N5O2S); Anal calcd for Cι9H27N5O2S: C, 58.59; H, 6.99; N, 17.98. Found: C, 58.26; H, 6.64; N, 17.69
Example 7
N'-[4-(4-Amino-2-butyl-l HH--iimmiiddaazzoo[[4,5-c]quinolin-l-yl)butyl]-
3-nitro- 1 -benzenesulfonamide Hydrochloride
Figure imgf000024_0001
According to the general method of Example 5, 3-nitrobenzenesulfonyl chloride and l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinoline-4-amine were combined. N1-
[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-3-nitro-l- benzenesulfonamide was isolated as the hydrochloride salt (white solid), m.p. 176.0-178.2 °C. Η NMR (300 MHz, DMSO-d6) δ 8.70 (very broad s, 2H), 8.49-8.42 (m, 2H), 8.21-
8.17 (m, 2H), 8.06 (t, J=5.7 Hz, IH), 7.88-7.81 (m, 2H), 7.71 (t, J=7.7 Hz, IH), 7.57 (t, J=7.7 Hz, IH), 4.56 (t, J=7.3 Hz, 2H), 2.94 (t, J=7.7 Hz, 2H), 2.86 (m, 2H), 1.81 (m, 4H), 1.60-1.42 (m, 4H), 0.96 (t, J=7.3 Hz, 3H); IR (KBr) 3096, 2954, 2869, 2771, 1671, 1607, 1528, 1351, 1335, 1163, 1 128, 1083, 879, 758, 735, 672, 661 cm" 1; MS (El) m/e 496.1897 (496.1893 calcd for C24H28N6O4S). Anal calcd for C24H28N6O4S*HCl*H2O: C, 52.31 ; H,
5.67; N, 15.25. Found: C, 52.26; H, 5.46; N, 15.09.
Example 8
N1-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
3-amino- 1 -benzenesulfonamide Hydrochloride
Figure imgf000025_0001
A solution of N'-[4-(4-amino-2-butyl- lH-imidazo[4,5-c]quinolin-l-yl)butyl]-3- nitro- 1 -benzenesulfonamide hydrochloride (0.4 g) in methanol (250 ml) was charged with a catalytic amount of 10% palladium on carbon (0.085 g). The reaction was placed under an atmosphere of hydrogen (50 psi; 3.44 X 105 Pa) and shaken on a Parr apparatus for 2 hours. The reaction mixture was filtered and the solvent removed in vacuo. The solid product was recrystallized from 2-propanol to provide 0.18 g of N'-[4-(4-amino-2-butyl- 1 H-imidazo[4,5-c]quinolin- 1 -yl)butyl]-3-amino- 1 -benzenesulfonamide hydrochloride as an off white crystalline solid, m.p. 110.2 °C (decomposition). Η NMR (300 MHz, DMSO-d6) δ 8.70 (very broad s, 2H), 8.22 (d, J=8.2 Hz, IH), 7.83 (d, J=7.8 Hz, IH), 7.72 (t, J=7.6 Hz, IH), 7.59 (t, J=7.7 Hz, IH), 7.43 (t, J=5.9 Hz, IH), 7.15 (t, J=7.9 Hz, IH),
6.95 (t, J=1.9 Hz, IH), 6.84 (d, J=7.7 Hz, IH), 6.73 (dd, J=8.0, 1.5 Hz, IH), 5.63 (broad s, 2H), 4.56 (t, J=7.5 Hz, 2H), 2.96 (t, J=7.7 Hz, 2H), 2.77 (q, J=6.3 Hz, 2H), 1.83 (m, 4H), 1.60-1.40 (m, 4H), 0.97 (t, J=7.3 Hz, 3H); IR (KBr) 3313, 3135, 2957, 2870, 2782, 1671, 1599, 1485, 1454, 1313, 1155, 1084, 754, 686 cm"1; MS (El) m/e 466.2150 (466.2151 calcd for C24H30N6O2S). Anal calcd for C24H30N6O2S*HC1*0.25H2O: C, 56.79; H, 6.26;
N, 16.56; CI, 6.98. Found: C, 56.87; H, 6.22; N, 16.19; CI, 7.22. Example 9
N i - [4-(4- Amino-2-butyl- 1 HH--iimmiiddaazzoo^ [4,5-c] quinolin- 1 -yl)butyl] -
4-nitro- 1 -benzenesulfonamide Hydrochloride
Figure imgf000026_0001
According to the general method of Example 5, 4-nitrobenzenesulfonyl chloride and l-(4-aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinoline-4-amine were combined. N1- [4-(4- Amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]-4-nitro- 1 - benzenesulfonamide was isolated as the hydrochloride salt (white solid), m.p. 96.0 °C (decomposition). Η NMR (300 MHz, DMSO-d6) δ 8.70 (very broad s, 2H), 8.38-8.34 (m,
2H), 8.19 (d, J=8.2 Hz, IH), 8.09 (t, J=5.6 Hz, IH), 8.03-7.99 (m, 2H), 7.80 (d, J=7.4 Hz, IH), 7.68 (t, J=7.4 Hz, IH), 7.54 (t, J=7.2 Hz, IH), 4.55 (t, J=7.4 Hz, 2H), 2.94 (t, J=7.7 Hz, 2H), 2.86 (q, J=6.2 Hz, 2H), 1.80 (m, 4H), 1.58 (m, 2H), 1.45 (q, J=7.5 Hz, 2H), 0.96 (t, J=7.3 Hz, 3H); IR (KBr) 3283, 3100, 2957, 2870, 2782, 1670, 1606, 1528, 1347, 1311, 1162, 1092, 854, 746, 737, 686 cm"1; MS (El) m/e 496.1902 (496.1893 calcd for
C24H28N6O4S). Anal calcd for C24H28N6O4S*HC1*0.85H2O: C, 52.57; H, 5.64; N, 15.33. Found: C, 52.57; H, 5.46; N, 15.33.
Example 10
N'-[4-(4-Amino-2-butyl-l lHH--iimmiiddaazzoo[[44,5-c]quinolin-l-yl)butyl]-
4-amino- 1 -benzenesulfonamide Hydrochloride
Figure imgf000027_0001
A solution of N -[4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-4- nitro-1 -benzenesulfonamide hydrochloride (0.38 g) in methanol (250 ml) was charged with a catalytic amount of 10% palladium on carbon (0.085 g). The reaction was placed under an atmosphere of hydrogen (50 psi; 3.44 X 105 Pa)) and shaken on a Parr apparatus for 2 hours. The reaction mixture was filtered and the solvent removed in vacuo. The solid product was recrystallized from 2-propanol to provide 0.34 g of N'-[4-(4-amino-2- butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-4-amino-l -benzenesulfonamide hydrochloride as an off white powder, m.p. 203.1-205.0 °C. Η NMR (300 MHz, DMSO- d6) δ 8.65 (very broad s, 2H), 8.2 l(d, J=8.0 Hz, IH), 7.82 (m, IH), 7.71 (t, J=7.7 Hz, IH), 7.58 (t, J=7.7 Hz, IH), 7.38 (d, J=8.7 Hz, 2H), 7.13 (t, J=5.9 Hz, IH), 6.60 (d, J=8.7 Hz,
2H), 5.92 (broad s, 2H), 4.55 (t, J=7.6 Hz, 2H), 2.96 (t, J=7.6 Hz, 2H), 2.70 (q, J=6.4 Hz, 2H), 1.81 (m, 4H), 1.58-1.43 (m, 4H), 0.96 (t, J=7.4 Hz, 3H); IR (KBr) 3430, 3316, 3215, 3046, 2955, 2868, 2679, 1671, 1594, 1334, 1157, 1091, 851, 776, 759 cm"1; MS (El) m e 466.2145 (466.2151 calcd for C24H30N6O2S). Anal calcd for C24H3oN6θ2S*HCl: C, 57.30; H, 6.21; N, 16.71. Found: C, 57.36; H, 6.31; N, 16.21. Example 11
N5-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
5-isoquinolinesulfonamide
Figure imgf000028_0001
A suspension of isoquinoline-5-sulfonyl chloride hydrochloride (0.83 g in 50 ml of pyridine, 3.1 mmol) was added dropwise to a stirring solution of l-(4-aminobutyl)-2- butyl-lH-imidazo[4,5-c]quinoline-4-amine (1.0 g, 3.2 mmol) and dichloromethane (175 ml). The solution turned a bright yellow color and was maintained at room temperature for 4 hours. An additional 0.18 g of isoquinoline-5-sulfonyl chloride hydrochloride was added and the reaction was maintained an additional 60 hours. The yellow solution was concentrated in vacuo, dissolved in dichloromethane, and washed sequentially with saturated aqueous sodium bicarbonate and water. The organic fraction was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethaneVmethanol) to provide 0.7 g of N5-[4-(4- amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-5-isoquinolinesulfonamide as a white crystalline solid, m.p. 96.0 °C (decomposition). Η NMR (300 MHz, DMSO-d6) δ 9.44 (d, J=0.7 Hz, IH), 8.64(d, J=6.1 Hz, IH), 8.41-8.35 (m, 2H), 8.30 (dd, J=7.4, 1.2 Hz, IH), 8.11 (t, J=5.6 Hz, IH), 7.92 (d, J=7.6 Hz, IH), 7.75 (t, J=7.7 Hz, IH), 7.61 (dd, J=8.3, 1.2 Hz, IH), 7.41 (dt, J=7.7, 1.2 Hz, IH), 7.22 (dt, J=7.6, 1.2 Hz, IH), 6.47 (broad s, 2H),
4.38 (t, J=7.5 Hz, 2H), 2.86-2.74 (m, 4H), 1.78-1.63 (m, 4H), 1.50-1.34 (m, 4H), 0.94 (t, J=7.4 Hz, 3H); MS (El) m/e 502.2151 (502.2151 calcd for C27H30N6O2S). Anal calcd for C27H30N6O2S: C, 64.52; H, 6.02; N, 16.72. Found: C, 64.03; H, 6.03; N, 16.55. Example 12 N-[4-(4-Amino-2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl] methanesulfonamide
Figure imgf000029_0001
Methanesulfonic anhydride (0.19 g, 1.1 mmol) was added to a stirring solution of l-(4-aminobutyl)-2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-4-amine (0.4 g, 1.07 mmol), dichloromethane (75 ml) and acetonitrile (100 ml). The reaction was maintained at room temperature for 60 hours. The solvent was removed in vacuo and the residue was purified by flash column chromatography (silica gel, 9: 1 dichloromethane\methanol). The fractions containing product were combined, washed with saturated aqueous sodium bicarbonate, dried (MgSO4), filtered, and concentrated to provide 0.3 g of N-[4-(4-amino- 2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl]methanesulfonamide as a white solid, m.p. 78.1-79.5 °C. Η NMR (300 MHz, DMSO-d6) δ 7.99 (d, J=7.6 Hz, IH), 7.62 (dd, J=8.3, 1.2 Hz, IH), 7.42 (m, IH), 7.27-7.21 (m, 3H), 6.98 (t, J=5.7 Hz, IH), 6.89
(d, J=8.7 Hz, 2H), 6.58 (broad s, 2H), 4.45 (broad s, 2H), 4.33 (s, 2H), 3.72 (s, 3H), 2.87 (m, 5H), 1.55 (broad s, 2H); MS (CI) m/e 454 (M+H).
Example 13 N'-[4-(4-Amino-lH-imidazo[4,5-c]quinolin-l-y)butyl]-l-butanesulfonamide
Figure imgf000029_0002
A solution of l-(4-aminobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (9.3 mg, 36 μmol) in 10 mL of dichloromethane in a screw-capped test tube was cooled down to -5°C. Butanesulfonyl chloride (45 μmol) was added as a 0.3 M solution in dichloromethane, with argon bubbling through the mixture during addition and for an additional 15 seconds. The mixture was allowed to stand at -5°C overnight. Aminomethyl polystyrene resin (ca. 90 mg, 0.62 meq/g, 100-200 mesh, Bachem) was added and the mixture was warmed to reflux and shaken at about 600 rpm fo 3 hours. The mixture was filtered through a Poly- Prep column (Bio-Rad #731-1550) to remove resin. Solvent was removed in vacuo and the residue was purified by semi-preparative hplc on a Gilson system (Rainin Microsorb C18 column , 21.4 x 250 mm, 8 micron particle size, 60A pore, 10 mL/min., gradient elution from 2-95% B in 25 min., hold at 95% B for 5 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi-prep hplc fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized. The solid was dissolved in ca. 3 mL of 2: 1 dichloromethane-methanol and shaken with ca. 80 mg (300 μmol) of diisopropylaminomethyl-polystyrene resin (Argonaut PS-DIEA, 3.86 mmol/g) for ~2 h to liberate the free amine, and then filtered and dried in vacuo to give the product as a solid. MS (APCI) m/ 376.16 (M+Η).
Example 14 N'-{4-[4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-
1 H-imidazo[4,5-c]quinolin- 1 -yl]butyl } -4-fluoro- 1 -benzenesulfonamide
Figure imgf000030_0001
According to the general method of Example 5, l-(4-aminobutyl)-2-(2- methoxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 4- fluorobenzenesulfonyl chloride were combined. Recrystallization from 4: 1 n-propyl acetate\methanol provided N1-{4-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinolin-l-yl]butyl}-4-fluoro-l -benzenesulfonamide as a white crystalline solid, m.p. 191.0-193.0 °C. Η NMR (300 MHz, DMSO-d6) δ 7.86-7.81 (m, 2H), 7.67 (broad s, IH), 7.45-7.39 (m, 2H), 5.65 (broad s, 2H), 4.15 (m, 2H), 3.76 (t, J=6.7 Hz, 2H), 3.27 (s, 3H), 3.00 (t, J=6.7 Hz, 2H), 2.90 (broad s, 2H), 2.78 (m, 2H), 2.65 (broad s, 2H), 1.75 (broad s, 4H), 1.61 (m, 2H), 1.43 (m, 2H); MS (CI) m/e 476 (M+H). Analysis:
Calculated for C23H30FN5O3S: %C, 58.09; %H, 6.36; %N, 14.73; Found: %C, 58.37; %H, 6.35; %N, 14.60.
Example 15 N-[4-(4-Amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
4-fluoro- 1 -benzenesulfonamide
Figure imgf000031_0001
Part A
A solution of benzoyl chloride (5.3 g, 37.7 mmol) in dichloromethane (100 mL) was slowly added to a solution of tert-butyl N-{4-[(3-aminoquinolin-4- yl)amino]butyl}carbamate (12.5 g, 37.7 mmol) in dichloromethane (250 mL) at ambient temperature. The reaction mixture was maintained at ambient temperature overnight. The resulting precipitate was isolated by filtration and dried to provide 11.0 g of tert-butyl N- (4-{ [3-(benzoylamino)quinolin-4-yl]amino}butyl)carbamate hydrochloride as a white solid.
Part B
Triethylamine (7.26 g, 71.7 mmol) was added to a solution of the material from Part A in ethanol (200 mL) and heated at reflux for 2 days. The reaction mixture was concentrated to provide an orange syrup. HPLC mass spec analysis showed that the syrup contained the desired product and starting material. The syrup was taken up in dichloromethane (100 mL) and then cooled in an ice bath. Triethylamine (5 mL) and benzoyl chloride (1.9 mL) were added. The reaction mixture was maintained at ambient temperature for 2 days at which time analysis by HPLC indicated that the reaction was not complete. The reaction mixture was concentrated under vacuum. The residue was taken up in isopropyl alcohol (150 mL). Triethylamine (5 mL) was added and the reaction mixture was heated at reflux overnight. The reaction mixture was concentrated under vacuum. The residue was purified by flash chromatography (silica gel; eluting with 10% methanol in dichloromethane). The fractions containing product were combined and concentrated under vacuum. The residue was recrystallized from acetonitrile to provide 6.7 g of tert-butyl N-[4-(2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]carbamate as a solid, m.p. 158-159°C.
Part C
3-Chloroperoxybenzoic acid (1.05 eq of 65%) was slowly added in small portions to a solution of tert-butyl N-[4-(2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]carbamate (6.56 g, 15.75 mmol) in dichloromethane (120 mL). After 3 hours the reaction was quenched with 1% aqueous sodium bicarbonate (200 mL). The layers were separated.
The aqueous layer was extracted with dichloromethane (2 X 50 mL). The organic fractions were combined, dried over magnesium sulfate and then concentrated under vacuum to provide a pale orange syrup. The syrup was triturated with diethyl ether to provide 6.8 g of l-[4-(tert-butylcarbamyl)butyl]-2-phenyl-lH-imidazo[4,5-c]quinoline- 5N-oxide as a pale tan solid, m.p. 178-181°C.
Part D
A solution of l-[4-(tert-butylcarbamyl)butyl]-2-phenyl-lH-imidazo[4,5- c]quinoline-5N-oxide (6.8 g, 15.75 mmol) in dichloromethane (100 mL) was chilled in an ice bath. Concentrated ammonium hydroxide (30 mL) was added. Tosyl chloride (3.0 g, 15.75 mmol) was added in small portions over a period of 30 minutes. The reaction mixture was allowed to warm to ambient temperature overnight. The reaction was quenched with water (350 mL). The layers were separated. The aqueous layer was extracted with dichloromethane. The organic fractions were combined, dried over magnesium sulfate and then concentrated under vacuum to provide a tan solid. This material was purified by flash chromatography (silica gel eluting with 10% methanol in dichloromethane) to provide 4.8 g of product. The bulk of the material was carried on to the next step. A small portion was recrystallized from toluene to provide tert-butyl N-[4- (4-amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]carbamate as a solid, m.p. 182- 183°C. Analysis: Calculated for C25Η29N5O2: %C, 69.58; %H, 6.77; %N, 16.22; Found: %C, 69.86; %H, 6.95; %N, 15.80. Part E The material from Part D was dissolved in methanol (15 mL) and 1 N hydrochloric acid (100 mL) and then heated at reflux for 2 hours. The reaction mixture was concentrated under vacuum to a volume of about 50 mL. Addition of concentrated ammonium hydroxide to pH 12 did not produce a precipitate. The pH was adjusted to 7 with 1 N hydrochloric acid. The mixture was extracted with dichloromethane and then with ethyl acetate. The aqueous layer was concentrated to dryness. The residue was dissolved in water (50 mL) and then extracted continuously with refluxing chloroform for 36 hours. The chloroform extract was concentrated under vacuum to provide a light tan solid. This material was recrystallized from acetonitrile to provide 2.5 g of l-(4- aminobutyl)-2-phenyl-lH-imidazo[4,5-c]quinolin-4-amine as an off white solid, m.p. 175- 177°C. Analysis: Calculated for C20Η2,N5: %C, 72.48; %H, 6.39; %N, 21.13; Found: %C,
72.72; %H, 6.32; %N, 20.71. Part F l-(4-Aminobutyl)-2-phenyl-lH-imidazo[4,5-c]quinolin-4-amine (0.331 g, 1.0 mmol) was dissolved in anhydrous acetonitrile (35 mL) and the solution was cooled to 4°C. A solution of 4-fluorobenzenesulfonyl chloride (0.194 g, 1.0 mmol) in anhydrous dichloromethane (10 mL) was slowly added. The reaction was allowed to slowly warm to ambient temperature over the weekend. The reaction was quenched by the addition of aqueous saturated sodium bicarbonate solution. The layers were separated and the organic layer was concentrated to provide a pale yellow solid. This material was recrystallized from isopropyl alcohol and then further purified by flash chromatography (silica gel eluting with 10% methanol in dichloromethane). The pure fractions were combined and concentrated. The residue was recrystallized from isopropyl alcohol to provide 0.2 g of N- [4-(4-amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-4-fluoro-l- benzenesulfonamide as a pale yellow solid, m.p. 214-216°C. Analysis: Calculated for C26Η24FN5O2S: %C, 63.79; %H, 4.94; %N, 14.30; Found: %C, 63.19; %H, 4.85; %N,
13.90. Mass spec M+l = 490.2 Example 16 N-[4-(4-Amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl] methanesulfonamide
Figure imgf000034_0001
Using the general method of Example 15 Part F, l-(4-aminobutyl)-2-phenyl-lH- imidazo[4,5-c]quinolin-4-amine (0.331 g, 1.0 mmol) was reacted with methanesulfonic anhydride to provide 0.14 g of N-[4-(4-Amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l- yl)butyl]methanesulfonamide as a white solid, m.p. 234-235°C. Mass spec M+l = 410.2.
Examples 17 - 33
The compounds shown in the Table below were prepared using the synthetic method described in Reaction Scheme II above. l-(2-Aminoethyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (25 mg) was placed in a 2 dram (7.4 mL) vial. Diisopropylethylamine (1 1 μL, 1.2 eq), dichloromethane (1 mL) and the sulfonyl chloride (1.1 eq) were added in order. The vial was placed on a shaker for about 2 hours and then on a sonicator for about 0.5 hours. The reaction mixture was allowed to stand at ambient temperature overnight and analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi-preparative ΗPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mlJmin., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi- prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Example 34
N-[2-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl] methanesulfonamide Trifluoroacetate
Figure imgf000038_0002
This compound was prepared using the method of Examples 17 - 33 above except that 1.1 eq of methanesulfonic anhydride was used in place of the sulfonyl chloride. (Observed Mass = 362.2)
Example 35
N- [2-(4-Amino-2-butyl- 1 H-imidazo [4,5-c] quinolin- 1 -yl)e thyl] trifluoromethanesulfonamide Trifluoroacetate
Figure imgf000039_0001
This compound was prepared using the method of Examples 17 - 33 above except that 1.1 eq of trifluoromethanesulfonic anhydride was used in place of the sulfonyl chloride. (Observed Mass = 416.1)
Examples 36 - 48
The compounds shown in the Table below were prepared using the synthetic method described in Reaction Scheme II above. l-(4-Aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (25 mg) was placed in a 2 dram (7.4 mL) vial. Diisopropylethylamine (14 μL, 1.0 eq), dichloromethane (1 mL) and the sulfonyl chloride (1.0 eq) were added in order. The vial was placed on a shaker for about 30 minutes at which time almost everything was in solution. Some time later a precipitate formed. A small amount of methanol was added and the precipitate dissolved. The reaction mixture was left on the shaker for an additional hour and then it was put on a sonicator for about 0.5 hours. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi-preparative ΗPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi- prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
Figure imgf000040_0001
Examples 41 - 52
The compounds shown in the Table below were prepared using the synthetic method described in Reaction Scheme II above. l-(4-Aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (25 mg) was placed in a 2 dram (7.4 mL) vial. Diisopropylethylamine (14 μL, 1.0 eq), dichloromethane (1 mL) and the sulfonyl chloride ( 1.0 eq) were added in order. The vial was placed on a sonicator at ambient temperature for about 60 minutes. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi-preparative ΗPLC (Capcell Pak C 18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi-prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Example 53 N-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl] trifluoromethanesulfonamide Trifluoroacetate
Figure imgf000044_0001
This compound was prepared using the method of Examples 41-52 above except that 1.0 eq of trifluoromethanesulfonic anhydride was used in place of the sulfonyl chloride. (Observed Mass = 444.1)
Examples 54 - 71 The compounds shown in the Table below were prepared using the synthetic method described in Reaction Scheme IV above. Part A
A catalytic amount of platinum (IV) oxide was added to a solution of l-(4- aminobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (2.75 g, 10.8 mmol) in trifluoroacetic acid (150 mL). The reaction mixture was placed under a hydrogen atmosphere at 50 psi
(3.44 X 105 Pa). After 1 week analysis by mass spectroscopy indicated the presence of both starting material and the tetrahydro product. Fresh catalyst was added to the reaction mixture and hydrogenation was continued at 50 psi (3.44 X 105 Pa). After 2 weeks the reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum. The residue was dissolved in IN hydrochloric acid (120 mL) and the solution was stirred at ambient temperature for 1 hour. The solution was made basic ( pΗ 10) by the addition of 50% sodium hydroxide and then extracted with dichloromethane (5 X 100 mL). The extracts were combined and concentrated under vacuum to provide 2.08 g of 1- (4-aminobutyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine as a white solid. Part B l-(4-Aminobutyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (25 mg) was placed in a 2 dram (7.4 mL) vial. Diisopropylethylamine (11 μL, 1.2 eq), dichloromethane (1 mL) and the sulfonyl chloride (1.1 eq) were added in order. The vial was placed on a shaker for about 6 hours. The reaction mixture was allowed to stand at ambient temperature overnight and was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi- preparative HPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Example 72 N-[4-(4-Amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl] methanesulfonamide Trifluoroacetate
Figure imgf000050_0001
This compound was prepared using the method of Examples 54 - 71 above except that 1.1 eq of methanesulfonic anhydride was used in place of the sulfonyl chloride.
(Observed Mass = 338.2)
Examples 73 - 201 The compounds in the table below were prepared according the synthetic method of Reaction Scheme II above using the following general method.
The lH-imidazo[4,5-c]quinolin-4-amine (50 mg) was placed in a 2 dram (7.4 mL) vial. Diisopropylethylamine (1.2 eq) in dichloromethane (-1 mL) was added. A solution containing the sulfonyl chloride (1.1 eq) in dichloromethane (~1 mL) was added. The vial was placed on a shaker for about 2 - 16 (usually 2) hours at ambient temperature. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi-preparative ΗPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi -prep ΗPLC fractions were analyzed by LC- APCI MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfonamide.
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Examples 202 - 213 The examples in the table below were prepared according to the synthetic method of Reaction Scheme VI above. Part A
The tetrahydroquinoline amine starting materials were prepared as follows. A catalytic amount of platinum (IV) oxide was added to a solution of l-(4- aminobutyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (2.2 g, 7.06 mmol) in trifluoroacetic acid (200 mL). The reaction mixture was hydrogenated at 50 psi (3.44 X 10 Pa) on a Parr apparatus for 6 days.. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum. The residue was combined with 1 N hydrochloric acid (100 mL) and heated on a steam bath for 2 hours. The mixture was cooled, made basic with ammonium hydroxide and then extracted with dichloromethane. The extract was concentrated under vacuum to provide of l-(4-aminobutyl)-2-butyl- 6,7,8,9-tetrahydro -lH-imidazo[4,5-c]quinolin-4-amine as a solid, m.p. 63-67°C
A catalytic amount of platinum (IV) oxide was added to a solution of l-(4- aminobutyl)-2-methoxyethyl-lH-imidazo[4,5-c]quinolin-4-amine (7.7 g, 24.5 mmol) in trifluoroacetic acid (250 mL). The reaction mixture was hydrogenated at 50 psi (3.44 X 105 Pa) on a Parr apparatus. The progress of the reaction was monitored by LC/MS. Additional catalyst was added 7, 11, and 17 days after the start of the reaction. After 25 days the reaction was complete. The reaction mixture was filtered through a layer of Celite® filter aid to remove the catalyst and the filtrate was concentrated under vacuum. The residue was combined with 1 N hydrochloric acid (100 mL) and stirred overnight. The mixture was made basic (pΗ = 11) with ammonium hydroxide and then extracted with dichloromethane (3 X 300 mL). The extracts were combined and concentrated under vacuum to provide 3.5 g of l-(4-aminobutyl)-6,7,8,9-tetrahydro-2-methoxyethyl-lH- imidazo[4,5-c]quinolin-4-amine as a solid.
Part B
The tetrahydroimidazoquinoline amines from Part A were reacted with the appropriate sulfonyl chloride using the method of Examples 73 - 201 above to provide the desired sulfonamide.
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Example 214
N-[4-(4-Amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)- lH-imidazo[4,5-c]quinolin-l-yl)butyl]methanesulfonamide Trifluoroacetat
Figure imgf000085_0001
This compound was prepare using the method of Examples 202 - 213 above except that methanesulfonic anhydride was used in place of the sulfonyl chloride.
Example 215 N-[4-(4-Amino-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-N-methyl-3,5- dimethylisooxazolo-4-sulfonamide Trifluoroacetate
Figure imgf000085_0002
Part A
Using the general method of Example DC001, l-(4-aminobutyl)-2-(2- methoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine was reacted with 3,5-dimethyloxazole-
4-sulfonyl chloride to provide N-[4-(4-amino -2-(2-methoxyethyl)-lH-imidazo[4,5- c]quinolin-l-yl)butyl] -3,5-dimethylisooxazolo-4-sulfonamide trifluoroacetate. Part B
Sodium hydride (5.8 mg) was added to a solution of the material from Part A (25.4 mg) in dimethylformamide. Iodomethane (3.2 μL) was added and the reaction mixture was shaken at ambient temperature for 2 hours. . The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi-preparative HPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi- prep HPLC fractions were analyzed by LC-APCI MS and the appropriate fractions were combined and lyophilized. The lyophilized material was purified a second time by semi- preparative HPLC using the same conditions except that the gradient elution from 5-95% B was run for 60 minutes instead of 10 minutes. The semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired amide.
Example 216 N-[4-(4- Amino -2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-N- methyltrifluoromethanesulfonamide Trifluoroacetate
Figure imgf000086_0001
This compound was prepared using the general method of Example 215 above, except that trifluoromethanesulfonic anhydride was used in place of the sulfonyl chloride in Part A.
Examples 217 - 221 The examples in the table below were prepare using the following general method. The lH-imidazo[4,5-c]quinolin-4-amine or the 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolin-4-amine (50 mg) was placed in a 2 dram (7.4 mL) vial. Dichloromethane (2 mL) and diisopropylethylamine (1.2 eq) were added. Dimethylsulfamoyl chloride (1.1 eq) was added. The vial was placed on a shaker for about 2 - 4 hours at ambient temperature. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi-preparative HPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min. , gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi-prep HPLC fractions were analyzed by LC- APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfamide.
Figure imgf000087_0001
Figure imgf000088_0001
Examples 222 - 228 The examples in the table below were prepared according to the synthetic method shown in Reaction Scheme V above. l-(4-Aminobutyl)-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine (50 mg) was placed in a 2 dram (7.4 mL) vial. 4-(Dimethylamino)pyridine (19 mg, 1.0 eq) and dichloromethane (800 μL) were added. The vial was sealed and cooled to -78°C in a dry ice/acetone bath. Sulfuryl chloride (186 μL of 1 M in dichloromethane) was added. The vial was put on a shaker for about 30 minutes and then cooled back down to -78°C. A separate vial was charged with the amine of formula R4R^NΗ (2.0 eq), triethylamine (2.0 eq) and dichloromethane (1 mL) and cooled to -78°C. The amine/triethylamine solution was added to the first vial. The vial was placed on a shaker at ambient temperature for about 1 hour. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The solvent was removed and the residue was purified by semi- preparative HPLC (Capcell Pak C18 column, 35 mm x 20 mm, 5 micron particle size, 20 mL/min., gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1 % trifluoroacetic acid/acetonitrile, peak detection at 254 nm for triggering fraction collection). The semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired sulfamide.
Figure imgf000089_0001
Figure imgf000090_0001
Examples 229 - 231 The examples in the table below were prepared using the method of Examples 222 - 228 above except that the amine of formula R4R NH was reacted with the sulfuryl chloride to provide the sulfamoyl chloride intermediate which was then reacted with 2.0 eq of l-(4-aminobutyl)-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine.
Figure imgf000091_0001
CYTOKINE INDUCTION IN HUMAN CELLS
An in vitro human blood cell system was used to assess cytokine induction by compounds of the invention. Activity is based on the measurement of interferon and tumor necrosis factor (α) (IFN and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995). Blood Cell Preparation for Culture
Whole blood is collected by venipuncture into EDTA vacutainer tubes from healthy human donors. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by density gradient centrifugation using Histopaque®-1077 (Sigma Chemicals, St. Louis, MO). The PBMCs are suspended at 3-4 x 106 cells/mL in RPMI
1640 medium containing 10 % fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin solution (RPMI complete). The PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound.
Compound Preparation
The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1 % for addition to the culture wells.
Incubation
The solution of test compound is added at 60 μM to the first well containing RPMI complete and serial (three fold or ten fold) dilutions are made. The PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range. The final concentration of PBMC suspension is 1.5-2 X 106 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37°C in a 5% carbon dioxide atmosphere.
Separation
Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm (-200 x g) at 4°C. The cell culture supernatant is removed with a sterile polypropylene pipet and transferred to sterile polypropylene tubes. Samples are maintained at -30 to - 70°C until analysis. The samples are analyzed for interferon (α) and tumor necrosis factor (α) by ELISA Interferon (α) and Tumor Necrosis Factor ( ) Analysis by ELISA
Interferon (α) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ.
Tumor necrosis factor (α) (TNF)concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA.
The table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound. A "**" indicates that no induction was seen at any of the tested concentrations (0.12, 0.37, 1.1 1, 3.33, 10 and 30 μM). A "***" indicates that no induction was seen at any of the tested concentrations (0.0001, 0.001, 0.01, 0.1, 1 and 10 μM).
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
The present invention has been described with reference to several embodiments thereof. The foregoing detailed description and examples have been provided for clarity of understanding only, and no unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made to the described embodiments without departing from the spirit and scope of the invention. Thus, the scope of the invention should not be limited to the exact details of the compositions and structures described herein, but rather by the language of the claims that follow.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula (I):
Figure imgf000099_0001
(I)
wherein
Rj is -alkyl-NR3- SO2 -X-R4 or -alkenyl-NR3- SO2 -X φ ;
X is a bond or -NR5-;
R is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of: -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -substituted cycloalkyl;
-substituted aryl; -substituted heteroaryl; -substituted heterocyclyl; -O-alkyl; -O-(alkyl)0-ι-aryl;
-O-(alkyl)o-ι -substituted aryl; -O-(alkyl)o- 1 -heteroaryl ;
-O-(alkyl)o-ι-substituted heteroaryl;
-O-(alkyl)0- 1 -heterocyclyl ;
-O-(alkyl)0- 1 -substituted heterocyclyl ; -COOH;
-CO-O-alkyl;
-CO-alkyl;
-S(O)o_2 -alkyl;
-S(O)o- -(alkyl)0-ι-aryl; -S(O)o-2-(alkyl)0-ι -substituted aryl;
-S(O)o_2 -(alkyl)o-ι -heteroaryl;
-S(O)o-2 -(alkyl)o-ι -substituted heteroaryl;
-S (O)o-2 -(alkyl)o- 1 -heterocyclyl ;
-S(O)o-2 -(alkyl)o-ι -substituted heterocyclyl; -(alkyl)0-1-NR3R3;
-(alkyl)o- 1 -NR3-CO-O-alkyl;
-(alkyl)0-i-NR3-CO-alkyl;
-(alkyl)0-ι-NR3-CO-aryl;
-(alkyl)o-ι-NR3-CO-substituted aryl; -(alkyl)o-ι-NR3-CO-heteroaryl;
-(alkyl)o- 1 -NR3-CO-substituted heteroaryl ;
-N3;
-halogen;
-haloalkyl; -haloalkoxy;
-CO-haloalkyl;
-CO-haloalkoxy;
-NO2;
-CN; -OH;
-SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo; R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
-substituted aryl; -heteroaryl; -substituted heteroaryl;
- alkyl-alkyl; - alkyl-O- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen; -N(R3)2;
-CO-N(R3)2;
-CO-Cio alkyl;
-CO-O-ci-io alkyl;
-N3; -aryl;
-substituted aryl;
-heteroaryl;
-substituted heteroaryl;
-heterocyclyl; -substituted heterocyclyl;
-CO-aryl;
-CO-(substituted aryl);
-CO-heteroaryl; and
-CO-(substituted heteroaryl); each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; Rs is selected from the group consisting of hydrogen and CMO alkyl, or R4 and R5 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; n is 0 to 4 and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 wherein X is a bond.
3. A compound of claim 2 wherein n is 0.
4. A compound of claim 2 wherein each R is hydrogen.
5. A compound of claim 2 wherein
Figure imgf000102_0001
is -(CH2)2- - NR3- SO2 -R4.
6. A compound of claim 2 wherein R is selected from the group consisting of alkyl, aryl and heteroaryl that may be unsubstituted or substituted by one or more substituents selected from the group consisting of:
-alkyl;
-alkenyl; -aryl;
-heteroaryl;
-heterocyclyl;
-substituted aryl;
-substituted heteroaryl; -substituted heterocyclyl;
-O-alkyl;
-O-(alkyl)0-i-aryl;
-O-(alkyl)o-ι -substituted aryl;
-O-(alkyl)o-ι-heteroaryl; -O-(alkyl)o-ι -substituted heteroaryl;
-O-(alkyl)o-ι-heterocyclyl;
-O-(alkyl)o-ι-substituted heterocyclyl; -COOH;
-CO-O-alkyl;
-CO-alkyl;
-S(O)o-2 -alkyl;
-S(O)o-2-(alkyl)0-,-aryl;
-S(O)o-2 -(alkyl)o-ι -substituted aryl;
-S (O)o-2 -(alkyl)o- 1 -heteroaryl ;
-S (O)0-2 -(alkyl)o- 1 -substituted heteroaryl ;
-S (O)0-2 -(alkyl)o- 1 -heterocyclyl ;
-S(O)o-2-(alkyl)o-ι -substituted heterocyclyl;
-(alkyl)o- NR3R3;
-(alkyl)o- -NR3-CO-O-alkyl;
-(alkyl)o- -NR3-CO-alkyl;
-(alkyl)o- -NR3-CO-aryl;
-(alkyl)o. -NR3-CO-substituted aryl;
-(alkyl)o- -NRs-CO-heteroaryl;
-(alkyl)o- -NR3-CO-substituted heteroaryl;
-N3;
-halogen;
-haloalkyl;
-haloalkoxy;
-CO-haloalkoxy;
-NO2;
-CN;
-OH;
-SH; and in the case of alkyl, oxo.
7. A compound of claim 2 wherein R is selected from the group consisting of hydrogen; alkyl; alkyl-O-alkyl; (alkyl)o-ι aryl, (alkyl)o-ι -(substituted aryl); (alkyl)o-r heteroaryl; and (alkyl)o-ι -(substituted heteroaryl).
8. A compound of claim 2 wherein R2 is selected from the group consisting of hydrogen, Cι-4alkyl, and Cι- alkyl-O- Cι-4alkyl.
9. A compound of claim 2 wherein the dashed bonds are absent.
10. A compound of claim 1 wherein X is -NR5-.
1 1. A compound of claim 10 wherein n is 0.
12. A compound of claim 10 wherein Ri is -(CH2)2_4- NR3- SO2 -NR5 -R4.
13. A compound of claim 10 wherein R2 is selected from the group consisting of hydrogen; alkyl; alkyl-O-alkyl; (alkyl)o-ι aryl, (alkyl)0_ι -(substituted aryl); (alkyl)o-ι- heteroaryl; and (alkyl)o-ι -(substituted heteroaryl).
14. A compound of claim 10 wherein R2 is selected from the group consisting of hydrogen, Cι- alkyl, and Cι-4alkyl-O- C]- alkyl.
15. A compound of claim 10 wherein R and R5 join to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring.
16. A compound of claim 10 wherein R4 and R5 join to form a substituted or unsubstituted pyrrolidine, moφholine, thiomoφholine, piperidine, or piperazine ring.
17. A compound of claim 16 wherein R3 is hydrogen.
18. A compound of claim 15 wherein R2 is selected from the group consisting of hydrogen; alkyl; alkyl-O-alkyl; (alkyl)o-ι aryl, (alkyl)o-ι -(substituted aryl); (alkyl)o-ι- heteroaryl; and (alkyl)o-ι -(substituted heteroaryl).
19. A compound of claim 16 wherein R is selected from the group consisting of hydrogen, C]-4alkyl, and Cι-4alkyl-O- Cι-4alkyl.
20. A compound of claim 10 wherein R and R5 are alkyl.
21. A compound of claim 20 wherein R3 is hydrogen.
22. A compound of claim 20 wherein R2 is selected from the group consisting of hydrogen; alkyl; alkyl-O-alkyl; (alkyl)o-ι aryl, (alkyl)o-ι -(substituted aryl); (alkyl)o-ι- heteroaryl; and (alkyl)o-r(substituted heteroaryl).
23. A compound of claim 10 wherein R3 is hydrogen.
24. A compound selected from the group consisting of:
N2-[2-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl]-2- thiophenesulfonamide; N'-[2-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl]-l- benzenesulfonamide;
N8-[2-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl]-8- quinolinesulfonamide;
N'-[2-(4-amino-2-butyl-lH-imidazo[4,5--]quinolin-l-yl)ethyl]-5-(dimethylamino)- 1 -naphthalenesulfonamide;
N-[4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l- yl)butyl]methanesulfonamide;
N ' -[4-(4-amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]- 1 - benzenesulfonamide ; N8-[4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-8- quinolinesulfonamide;
N2-[4-(4-amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]-2- thiophenesulfonamide ;
N2-[4-(4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-2- thiophenesulfonamide;
N1-[4-(4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-l- benzenesulf onamide ; N8-[4-(4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-8- quinolinesulfonamide;
N1-[4-(4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-5-
(dimethylamino)-l -naphthalenesulfonamide; N'-[4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-4-fluoro-l- benzenesulf onamide ;
N1-[4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-3-fluoro-l- benzenesulfonamide;
N- { 2-[4-amino-2-(ethoxymethyl)- lH-imidazo[4,5-c]quinolin- 1 - yl]ethyl}methanesulfonamide;
N2-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl}-2- thiophenesulfonamide ;
N1- { 2-[4-amino-2-(ethoxymethyl)- lH-imidazo[4,5-c]quinolin- 1 -yl]ethyl } -5-
(dimethylamino)- 1 -naphthalenesulfonamide; N- {4-[4-amino-2-(2-methoxyethyl)- lH-imidazo[4,5-c]quinolin- 1 - yl]butyl Jmethanesulfonamide;
N2-{4-[4-amino-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl}-2- thiophenesulfonamide;
N ' - { 4-[4-amino-2-(2-methoxyethyl)- 1 H-imidazo[4,5-c]quinolin- 1 -yl]butyl } -5- (dimethylamino)- 1 -naphthalenesulfonamide;
N ' - { 4-[4-amino-2-(2-methoxyethyl)- lH-imidazo[4,5-c]quinolin- 1 -yl]butyl } -4- fluoro- 1 -benzenesulfonamide;
N'-{4-[4-amino-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl}-3- fluoro- 1 -benzenesulfonamide; N1 - { 4-[4-amino-2-(2-methoxyethyl)- lH-imidazo[4,5-c]quinolin- 1 -yl]butyl } - 1 - benzenesulfonamide ;
N8- { 4- [4-amino-2-(2-methoxyethyl)- 1 H-imidazo[4,5-c]quinolin- 1 -yljbutyl } -8- quinolinesulfonamide;
N2-{4-[4-amino-2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl}-2- thiophenesulfonamide;
N-[4-(4-an--ino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l- yl)butyl]methanesulfonamide; N2-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
2-thiophenesulfonamide;
N1-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
5-(dimethylamino)-l -naphthalenesulfonamide; N1 {-4-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5- cjquinolin- 1 -yl]butyl } - 1 -benzenesulfonamide;
N ' - { 4- [4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro- 1 H-imidazo[4,5- c]quinolin- 1 -yl]butyl } -5-(dimethylamino)- 1 -naphthalenesulfonamide;
N'-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl}-N,N- dimethylsulfamide;
N - { 4- [4-amino-2-(2-methoxyethyl)- lH-imidazo[4,5-c]quinolin- 1 -yl]butyl } -N,N- dimethylsulfamide;
N'-{4-[4-amino-2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl}-N,N- dimethylsulfamide; N'-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
NN-dimethylsulfamide ;
Ν'-{4-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-
1 -yl]butyl } -N,N-dimethylsulfamide;
Ν4-{4-[4-amino-2-(2-methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl}-4- thiomoφholinesulfonamide;
N ' - { 4- [4-amino-2-(2-methoxyethyl)- 1 H-imidazo[4,5-c ] quinolin- 1 -yljbutyl } - 1 - pyrrolidinesulfonamide;
N1-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
4-fluoro- 1 -benzenesulfonamide; N-[4-(4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin- l-yl)butyl]methanesulfonamide; and
N- { 4-[4-amino-2-(2-methoxyethyl)- lH-imidazo[4,5-c]quinolin- 1 -yl]butyl } phenyl- methanesulfonamide.
25. A compound selected from the group consisting of:
N1-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]- 5-(dimethylamino)-l -naphthalenesulfonamide;
N'-[4-(4- Amino- lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
5-(dimethylamino)- 1 -naphthalenesulfonamide;
N2-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]- 2-thiophenesulfonamide;
N-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]- phenylmethanesulfonamide;
N1-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
1 -benzenesulfonamide; N-[4-(4-Amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]
Methanesulfonamide;
N1 -[4-(4-Amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]-
3-nitro-l -benzenesulfonamide;
N ' -[4-(4- Amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]- 3-amino-l -benzenesulfonamide;
N'-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
4-nitro- 1 -benzenesulfonamide;
N ' -[4-(4-Amino-2-butyl- 1 H-imidazo[4,5-c]quinolin- 1 -yl)butyl]-
4-amino- 1 -benzenesulfonamide; N5-[4-(4-Amino-2-butyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]-
5-isoquinolinesulfonamide
N-[4-(4-Amino-2-(4-methoxybenzyl)-lH-imidazo[4,5-c]quinolin-l-yl]butyl]- methanesulfonamide;
N1-[4-(4-Amino-lH-imidazo[4,5-c]quinolin-l-y)butyl]-l-butanesulfonamide; N1-{4-[4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin- 1 -yl]butyl } -4-fluoro- 1 -benzenesulfonamide;
N1-[4-(4-Amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-
4-fluoro- 1 -benzenesulfonamide; and
N-[4-(4-Amino-2-phenyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl] methanesulfonamide.
26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
27. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable carrier.
29. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 1 to the animal.
30. A method of treating a viral disease in an animal comprising administering an effective amount of a compound of claim 1 to the animal.
31. A method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound of claim 1 to the animal.
32. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 2 to the animal.
33. A method of treating a viral disease in an animal comprising administering an effective amount of a compound of claim 2 to the animal.
34. A method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound of claim 2 to the animal.
35. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 10 to the animal.
36. A method of treating a viral disease in an animal comprising administering an effective amount of a compound of claim 10 to the animal.
37. A method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound of claim 10 to the animal.
PCT/US2000/015722 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines WO2000076519A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SK1792-2001A SK286418B6 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines, pharmaceutical composition comprising the same and their use
EP00938211A EP1198233B1 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
EEP200100669A EE05074B1 (en) 1999-06-10 2000-06-08 Sulphonamide- and sulphamide-substituted imidazoquinolines, their use in therapy and pharmaceutical preparations containing them
IL14648600A IL146486A0 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide susbtituted imidazoquinolines
DE60030126T DE60030126T2 (en) 1999-06-10 2000-06-08 SULPHONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOCHINOLINE
NZ515967A NZ515967A (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
HU0201431A HU229928B1 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
CA2376305A CA2376305C (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
BRPI0011433-2B1A BR0011433B1 (en) 1999-06-10 2000-06-08 IMMEDAZOKININE COMPOUNDS REPLACED WITH SULFONAMIDE AND SULFAMIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
JP2001502852A JP4833466B2 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
AU53284/00A AU772179B2 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
PL352554A PL211009B1 (en) 1999-06-10 2000-06-08 Sulfonamide or sulfamide substituted amidazoquinolines
MXPA01012547A MXPA01012547A (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines.
SI200030908T SI1198233T1 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines
UA2001128448A UA73503C2 (en) 1999-06-10 2000-08-06 Imidazoquinolines substituted by sulfonamide and sulfamide
NO20015502A NO320747B1 (en) 1999-06-10 2001-11-09 Sulfonamide and sulfamide substituted imidazoquinolines
IL146486A IL146486A (en) 1999-06-10 2001-11-14 1-(sulfonamide and sulfamide substituted)-1h-imidazo[4,5-c]quinoline-4-amines and pharmaceutical compositions containing them
HR20010890A HRP20010890B1 (en) 1999-06-10 2001-11-29 Sulfonamides and sulfonamide substituted imidazoquinolines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13836599P 1999-06-10 1999-06-10
US60/138,365 1999-06-10
US09/589,216 US6331539B1 (en) 1999-06-10 2000-06-07 Sulfonamide and sulfamide substituted imidazoquinolines
US09/589,216 2000-06-07

Publications (1)

Publication Number Publication Date
WO2000076519A1 true WO2000076519A1 (en) 2000-12-21

Family

ID=26836139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015722 WO2000076519A1 (en) 1999-06-10 2000-06-08 Sulfonamide and sulfamide substituted imidazoquinolines

Country Status (29)

Country Link
US (5) US6331539B1 (en)
EP (1) EP1198233B1 (en)
JP (1) JP4833466B2 (en)
KR (1) KR100781428B1 (en)
CN (1) CN1249061C (en)
AT (1) ATE336249T1 (en)
AU (1) AU772179B2 (en)
BR (1) BR0011433B1 (en)
CA (1) CA2376305C (en)
CY (1) CY1108536T1 (en)
CZ (1) CZ303287B6 (en)
DE (1) DE60030126T2 (en)
DK (1) DK1198233T3 (en)
EE (1) EE05074B1 (en)
ES (1) ES2270840T3 (en)
HK (1) HK1086762A1 (en)
HR (1) HRP20010890B1 (en)
HU (1) HU229928B1 (en)
IL (2) IL146486A0 (en)
MX (1) MXPA01012547A (en)
NO (1) NO320747B1 (en)
NZ (1) NZ515967A (en)
PL (1) PL211009B1 (en)
PT (1) PT1198233E (en)
RU (1) RU2248975C2 (en)
SK (1) SK286418B6 (en)
TR (1) TR200103575T2 (en)
UA (1) UA73503C2 (en)
WO (1) WO2000076519A1 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046194A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Substituted imidazopyridines
WO2002046190A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
WO2003050117A1 (en) * 2001-12-06 2003-06-19 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
EP1360486A2 (en) * 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
WO2003097641A2 (en) * 2002-05-21 2003-11-27 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
US6706728B2 (en) 1999-01-08 2004-03-16 3M Innovative Properties Company Systems and methods for treating a mucosal surface
WO2004058759A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP1455700A2 (en) * 2001-11-16 2004-09-15 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
EP1542688A2 (en) * 2002-09-26 2005-06-22 3M Innovative Properties Company 1h-imidazo dimers
WO2005066169A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US6924293B2 (en) 2001-12-21 2005-08-02 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1638566A2 (en) * 2003-06-27 2006-03-29 3M Innovative Properties Company Sulfonamide substituted imidazoquinolines
EP1653959A2 (en) * 2003-08-14 2006-05-10 3M Innovative Properties Company Lipid-modified immune response modifiers
EP1658076A1 (en) * 2003-08-27 2006-05-24 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20060195067A1 (en) * 2003-08-25 2006-08-31 Wolter James T Delivery of immune response modifier compounds
JP2007501252A (en) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー Formulation containing immune response modifier
EP1830880A2 (en) * 2004-12-30 2007-09-12 Coley Pharmaceutical Group, Inc. Multi-route administration of immune response modifier compounds
WO2008067995A2 (en) * 2006-12-05 2008-06-12 Transgene S.A. Means and method for raising improved immune response
KR101052387B1 (en) 2006-12-29 2011-07-28 일양약품주식회사 Solid phase form of racemic ilaprazole
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
US8063051B2 (en) 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
US8067411B2 (en) 2006-12-14 2011-11-29 Astrazeneca Ab Compounds
US8067413B2 (en) 2007-03-19 2011-11-29 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US8673907B2 (en) 2007-12-17 2014-03-18 Astrazeneca Ab Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
US9045472B2 (en) 2010-12-16 2015-06-02 Astrazeneca Ab Imidazoquinoline compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9441005B2 (en) 2011-05-18 2016-09-13 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US11110178B2 (en) 2016-07-07 2021-09-07 The Board Of Trustees Of The Leland Standford Junior University Antibody adjuvant conjugates
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
PT1478327E (en) 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
CA2484044A1 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
DE60335350D1 (en) * 2002-03-19 2011-01-27 Powderject Res Ltd ADJUVANTIES FOR DNA VACCINES BASED ON IMIDAZOCHINOLINE
DE50308334D1 (en) * 2002-05-07 2007-11-22 Schott Ag Lighting device for buttons
CN1674894A (en) * 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
DK1545597T3 (en) 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
CA2506415A1 (en) * 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (en) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
ATE556711T1 (en) * 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
WO2004080292A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
JP2006523212A (en) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20080039533A1 (en) * 2003-07-31 2008-02-14 3M Innovative Properties Company Bioactive Compositions Comprising Triazines
JP2007502288A (en) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
ES2545826T3 (en) * 2003-08-14 2015-09-16 3M Innovative Properties Company Lipid Modified Immune Response Modifiers
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co Methods related to the treatment of mucosal associated conditions
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co Selective modulation of tlr gene expression
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR20060120069A (en) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
KR20060117329A (en) * 2003-11-21 2006-11-16 노파르티스 아게 1h-imidazoquinoline derivatives as protein kinase inhibitors
AR046845A1 (en) * 2003-11-21 2005-12-28 Novartis Ag DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
AU2004312510A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
JP2007517035A (en) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
ES2665342T3 (en) * 2004-03-15 2018-04-25 Meda Ab Formulations and methods for immune response modifiers
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
CN101426524A (en) * 2004-04-28 2009-05-06 3M创新有限公司 Compositions and methods for mucosal vaccination
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
PL1789042T3 (en) * 2004-09-02 2012-09-28 3M Innovative Properties Co 1-alkoxy 1h-imidazo ring systems and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
ES2392647T3 (en) 2004-12-30 2012-12-12 3M Innovative Properties Company Chiral tetracyclic compounds that induce interferon biosynthesis
KR20070107685A (en) * 2004-12-30 2007-11-07 다케다 야쿠힌 고교 가부시키가이샤 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
ES2475728T3 (en) 2005-02-09 2014-07-11 3M Innovative Properties Company Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008532933A (en) 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ,インコーポレイテッド Substituted imidazoquinolines and substituted imidazonaphthyridines
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
PL2351772T3 (en) 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP1850849A2 (en) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ,インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008533148A (en) 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー Treatment method for actinic keratosis
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
EP2614709A1 (en) 2005-07-18 2013-07-17 Novartis AG Small animal model for HCV replication
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
CN102755645A (en) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 Influenza vaccines with reduced amount of emulsion adjuvant
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2368572T (en) 2005-11-04 2020-06-16 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007079203A2 (en) * 2005-12-28 2007-07-12 3M Innovative Properties Company Treatment for cutaneous t cell lymphoma
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
NZ570973A (en) * 2006-03-22 2011-11-25 Hoffmann La Roche Pyrazole-amide-adamantane derivatives as 11-beta-HSD-1 inhibitors
ES2388556T3 (en) * 2006-03-23 2012-10-16 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
BRPI0713711A2 (en) * 2006-06-20 2012-10-30 Transgene Sa recombinant viral vaccine, vaccination kit, and method for using at least one compound
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
ES2536401T3 (en) 2006-09-11 2015-05-25 Novartis Ag Making vaccines against influenza viruses without using eggs
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AR065784A1 (en) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.
CA2686163A1 (en) * 2007-05-08 2008-11-13 Astrazenca Ab Imidazoquinolines with immuno-modulating properties
WO2009001217A2 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP3459563A1 (en) 2008-03-18 2019-03-27 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US20110312525A1 (en) 2009-01-20 2011-12-22 Bruce Acres Soluble icam-1 as biomarker for prediction of therapeutic response
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
MX2011010061A (en) 2009-03-24 2011-11-18 Transgene Sa Biomarker for monitoring patients.
CN102439153B (en) 2009-03-25 2015-07-22 德克萨斯大学系统董事会 Compositions for stimulation of mammalian innate immune resistance to pathogens
MX363222B (en) 2009-04-14 2019-03-15 Novartis Ag Compositions for immunising against staphylococcus aerus.
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CN102483405B (en) 2009-07-10 2015-12-02 特朗斯吉有限公司 For selecting biomarker and the correlation technique of patient
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
PT2464658E (en) 2009-07-16 2015-01-14 Novartis Ag Detoxified escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
NO2575876T3 (en) 2010-05-26 2018-05-05
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modified nicotinic compounds and related methods
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
LT3275892T (en) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Pre-fusion rsv f antigens
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
MX355623B (en) 2011-06-03 2018-04-25 3M Innovative Properties Co Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom.
US20140228315A1 (en) * 2011-06-16 2014-08-14 Children's Hospital Medical Center Blockade of eosinophil production by toll-like receptors
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
AU2014203896B2 (en) 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
JP6446054B2 (en) 2013-11-05 2018-12-26 スリーエム・イノベイティブ・プロパティーズ・カンパニー Sesame oil-based injection formulation
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
SI3122378T1 (en) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
JP6760919B2 (en) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド Anti-PD-L1 combination for treating tumors
CN112546231A (en) 2014-07-09 2021-03-26 博笛生物科技有限公司 Combination therapeutic compositions and combination therapeutic methods for treating cancer
CN112587672A (en) 2014-09-01 2021-04-02 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US11680244B2 (en) 2015-05-20 2023-06-20 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
JP6956071B2 (en) 2015-08-31 2021-10-27 スリーエム イノベイティブ プロパティズ カンパニー Imidazo [4,5-c] cyclic compound containing a substituted guanidine group
KR20180041745A (en) 2015-08-31 2018-04-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Guanidine substituted imidazo [4,5-c] cyclic compound
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
WO2017075389A1 (en) 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
CN115350279A (en) 2016-01-07 2022-11-18 博笛生物科技有限公司 anti-HER 2 combinations for the treatment of tumors
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
US10821094B2 (en) 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
WO2018038877A1 (en) 2016-08-26 2018-03-01 3M Innovative Properties Company FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS
CN110234401B (en) 2016-11-09 2024-03-01 德克萨斯大学系统董事会 Methods and compositions for adaptive immunomodulation
WO2018160552A1 (en) 2017-03-01 2018-09-07 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
JP7080501B2 (en) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
CN111511740B (en) 2017-12-20 2023-05-16 3M创新有限公司 Amide substituted imidazo [4,5-C ] quinoline compounds with branched linking groups for use as immune response modifiers
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
US11370788B2 (en) 2018-02-28 2022-06-28 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group
CA3034912A1 (en) 2018-02-28 2019-08-28 Pfizer Inc. Il-15 variants and uses thereof
MX2020012607A (en) 2018-05-23 2021-01-29 Pfizer Antibodies specific for gucy2c and uses thereof.
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20210323962A1 (en) 2018-11-26 2021-10-21 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP3980415A1 (en) 2019-06-06 2022-04-13 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220194935A1 (en) 2019-06-12 2022-06-23 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
BR112022009723A2 (en) 2019-12-17 2022-08-09 Pfizer SPECIFIC ANTIBODIES TO CD47, PD-L1, AND USES THEREOF
CN116323668A (en) 2020-07-17 2023-06-23 辉瑞公司 Therapeutic antibodies and uses thereof
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09208584A (en) * 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US5500228A (en) * 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5750134A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
ES2071340T3 (en) * 1990-10-05 1995-06-16 Minnesota Mining & Mfg PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS.
US5977306A (en) 1991-02-12 1999-11-02 Heska Corporation Parasitic helminth P39 proteins, and uses thereof
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
ATE155681T1 (en) * 1992-05-18 1997-08-15 Minnesota Mining & Mfg DEVICE FOR TRANSMUCOSAL ACTIVE DELIVERY
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
GB9420168D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
ATE367159T1 (en) * 1996-10-25 2007-08-15 Minnesota Mining & Mfg COMPOUNDS THAT ALTER THE IMMUNE RESPONSE FOR THE TREATMENT OF TH2-MEDIATED AND RELATED DISEASES
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JPH10298181A (en) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd Type 2 helper t cell selective immune response inhibitor
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
JPH1180156A (en) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1-(substitutedaryl)alkyl-1h-imidazopyridin-4-amine derivative
JPH11108156A (en) 1997-10-09 1999-04-20 Tochigi Fuji Ind Co Ltd Differential device
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
US6182186B1 (en) 1998-06-30 2001-01-30 Sun Microsystems, Inc. Method and apparatus that utilizes lock states to lock resources
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
WO2000019987A1 (en) 1998-10-02 2000-04-13 3M Innovative Properties Company Mucosal originated drug delivery systems and animal applications
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1140091B1 (en) * 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
DE10029580C1 (en) * 2000-06-15 2002-01-10 Ferton Holding Sa Device for removing body stones with an intracorporeal lithotripter
AU2001280551B9 (en) 2000-07-13 2006-01-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ic
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
WO2002046479A1 (en) * 2000-12-07 2002-06-13 Aoyama Seisakusho Co., Ltd. Method for baking steel part
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20020110840A1 (en) * 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
JP2002247884A (en) 2001-02-19 2002-08-30 Hitachi Ltd Operation controller for fan motor
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
WO2003094836A2 (en) * 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT1478327E (en) * 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
AU2003233519A1 (en) * 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CN1674894A (en) * 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
DK1545597T3 (en) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
JP2006503068A (en) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
JP2006513212A (en) * 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) * 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (en) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
ATE556711T1 (en) * 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
JP2006523212A (en) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
WO2004080292A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
JP2004302671A (en) * 2003-03-28 2004-10-28 Hitachi Software Eng Co Ltd Database search path designating method
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions and methods for induction of opioid receptors
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
DE602004026891D1 (en) * 2003-09-05 2010-06-10 Anadys Pharmaceuticals Inc TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09208584A (en) * 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706728B2 (en) 1999-01-08 2004-03-16 3M Innovative Properties Company Systems and methods for treating a mucosal surface
WO2002046190A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
WO2002046194A3 (en) * 2000-12-08 2003-02-06 3M Innovative Properties Co Substituted imidazopyridines
WO2002046190A3 (en) * 2000-12-08 2003-07-17 3M Innovative Properties Co Sulfonamido ether substituted imidazoquinolines
EP1360486A2 (en) * 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
WO2002046194A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Substituted imidazopyridines
EP1455700A4 (en) * 2001-11-16 2007-02-14 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor pathways
EP1719511A2 (en) * 2001-11-16 2006-11-08 3M Innovative Properties Company N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
JP2006249102A (en) * 2001-11-16 2006-09-21 Three M Innovative Properties Co N-[4-(4-amino-2-ethyl-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide or its pharmaceutically permissible salt
JP4550775B2 (en) * 2001-11-16 2010-09-22 コーリー ファーマシューティカル グループ,インコーポレイテッド N- [4- (4-Amino-2-ethyl-1H-imidazo [4,5-c] quinolin-1-yl] butyl] methanesulfonamide, or a pharmaceutically acceptable salt thereof
EP1455700A2 (en) * 2001-11-16 2004-09-15 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
EP1719511A3 (en) * 2001-11-16 2006-11-22 3M Innovative Properties Company N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
AU2002312414B2 (en) * 2001-12-06 2009-02-19 Coley Pharmaceutical Group, Inc. Sulfonamido substituted imidazopyridines
CN100372846C (en) * 2001-12-06 2008-03-05 3M创新有限公司 Sulfonamido substituted imidazopyridines
WO2003050117A1 (en) * 2001-12-06 2003-06-19 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6924293B2 (en) 2001-12-21 2005-08-02 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7199131B2 (en) 2001-12-21 2007-04-03 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2003097641A3 (en) * 2002-05-21 2004-05-06 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
US7998972B2 (en) 2002-05-21 2011-08-16 Novartis Ag 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
WO2003097641A2 (en) * 2002-05-21 2003-11-27 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
EP1542688A4 (en) * 2002-09-26 2010-06-02 3M Innovative Properties Co 1h-imidazo dimers
EP1542688A2 (en) * 2002-09-26 2005-06-22 3M Innovative Properties Company 1h-imidazo dimers
US7598382B2 (en) 2002-12-20 2009-10-06 Coley Pharmaceutical Group, Inc. Aryl substituted imidazoquinolines
WO2004058759A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP1638566A2 (en) * 2003-06-27 2006-03-29 3M Innovative Properties Company Sulfonamide substituted imidazoquinolines
EP1638566A4 (en) * 2003-06-27 2009-03-25 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
JP2007501252A (en) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー Formulation containing immune response modifier
US8221771B2 (en) 2003-08-05 2012-07-17 3M Innovative Properties Company Formulations containing an immune response modifier
EP2939693A1 (en) * 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
EP1653959A2 (en) * 2003-08-14 2006-05-10 3M Innovative Properties Company Lipid-modified immune response modifiers
EP1653959A4 (en) * 2003-08-14 2009-04-08 3M Innovative Properties Co Lipid-modified immune response modifiers
US8961477B2 (en) * 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20060195067A1 (en) * 2003-08-25 2006-08-31 Wolter James T Delivery of immune response modifier compounds
EP1658076A4 (en) * 2003-08-27 2009-02-25 3M Innovative Properties Co Aryloxy and arylalkyleneoxy substituted imidazoquinolines
KR101106812B1 (en) * 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines
EP1658076A1 (en) * 2003-08-27 2006-05-24 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005066169A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20090062272A1 (en) * 2003-12-30 2009-03-05 Bonk Jason D Imidazoquinolinyl sulfonamides
WO2005066169A3 (en) * 2003-12-30 2005-11-10 3M Innovative Properties Co Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US8735421B2 (en) * 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US8969362B2 (en) 2004-03-26 2015-03-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
US8575180B2 (en) 2004-03-26 2013-11-05 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
EP1830880A4 (en) * 2004-12-30 2008-03-26 Coley Pharm Group Inc Multi-route administration of immune response modifier compounds
EP1830880A2 (en) * 2004-12-30 2007-09-12 Coley Pharmaceutical Group, Inc. Multi-route administration of immune response modifier compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
WO2008067995A2 (en) * 2006-12-05 2008-06-12 Transgene S.A. Means and method for raising improved immune response
WO2008067995A3 (en) * 2006-12-05 2008-10-02 Transgene Sa Means and method for raising improved immune response
US8067411B2 (en) 2006-12-14 2011-11-29 Astrazeneca Ab Compounds
KR101052387B1 (en) 2006-12-29 2011-07-28 일양약품주식회사 Solid phase form of racemic ilaprazole
US8067413B2 (en) 2007-03-19 2011-11-29 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
US8063051B2 (en) 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
US8673907B2 (en) 2007-12-17 2014-03-18 Astrazeneca Ab Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
US9045472B2 (en) 2010-12-16 2015-06-02 Astrazeneca Ab Imidazoquinoline compounds
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
US9441005B2 (en) 2011-05-18 2016-09-13 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US11110178B2 (en) 2016-07-07 2021-09-07 The Board Of Trustees Of The Leland Standford Junior University Antibody adjuvant conjugates
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Also Published As

Publication number Publication date
PT1198233E (en) 2007-01-31
PL352554A1 (en) 2003-08-25
PL211009B1 (en) 2012-03-30
NO320747B1 (en) 2006-01-23
HU229928B1 (en) 2015-01-28
BR0011433B1 (en) 2013-10-22
HUP0201431A2 (en) 2002-08-28
ES2270840T3 (en) 2007-04-16
NO20015502L (en) 2002-02-07
DE60030126D1 (en) 2006-09-28
NO20015502D0 (en) 2001-11-09
HK1086762A1 (en) 2006-09-29
US20040204438A1 (en) 2004-10-14
EP1198233A1 (en) 2002-04-24
US7030131B2 (en) 2006-04-18
TR200103575T2 (en) 2002-06-21
UA73503C2 (en) 2005-08-15
US6331539B1 (en) 2001-12-18
CN1249061C (en) 2006-04-05
US6800624B2 (en) 2004-10-05
DK1198233T3 (en) 2006-12-04
NZ515967A (en) 2003-10-31
BR0011433A (en) 2002-03-05
AU772179B2 (en) 2004-04-08
EP1198233A4 (en) 2002-07-24
EE200100669A (en) 2003-02-17
US20040029877A1 (en) 2004-02-12
CZ20014363A3 (en) 2002-03-13
HUP0201431A3 (en) 2002-12-28
RU2248975C2 (en) 2005-03-27
MXPA01012547A (en) 2003-10-14
US20030130299A1 (en) 2003-07-10
IL146486A0 (en) 2002-07-25
HRP20010890B1 (en) 2011-03-31
KR100781428B1 (en) 2007-12-03
CN1354663A (en) 2002-06-19
EE05074B1 (en) 2008-10-15
JP4833466B2 (en) 2011-12-07
AU5328400A (en) 2001-01-02
HRP20010890A2 (en) 2003-08-31
CY1108536T1 (en) 2014-04-09
SK286418B6 (en) 2008-09-05
JP2003501474A (en) 2003-01-14
DE60030126T2 (en) 2007-03-15
CZ303287B6 (en) 2012-07-18
SK17922001A3 (en) 2002-04-04
ATE336249T1 (en) 2006-09-15
EP1198233B1 (en) 2006-08-16
US20060106052A1 (en) 2006-05-18
US6825350B2 (en) 2004-11-30
CA2376305A1 (en) 2000-12-21
IL146486A (en) 2010-05-31
CA2376305C (en) 2010-10-12
KR20020010701A (en) 2002-02-04

Similar Documents

Publication Publication Date Title
US6331539B1 (en) Sulfonamide and sulfamide substituted imidazoquinolines
US6677349B1 (en) Sulfonamide and sulfamide substituted imidazoquinolines
US6780873B2 (en) Urea substituted imidazoquinolines
WO2005003064A2 (en) Sulfonamide substituted imidazoquinolines
EP1343784A2 (en) Urea substituted imidazoquinoline ethers
AU2002232497A1 (en) Urea substituted imidazoquinoline ethers
AU2002239517A1 (en) Sulfonamido ether substituted imidazoquinolines
EP1642580B1 (en) Sulfonamide substituted imidazoquinolines
EP1438958A1 (en) Carbamate substituted imidazoquinolines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808683.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 53284/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20010890A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012547

Country of ref document: MX

Ref document number: PV2001-4363

Country of ref document: CZ

Ref document number: IN/PCT/2001/1714/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2376305

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 17922001

Country of ref document: SK

Ref document number: 515967

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020017015844

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 502852

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/03575

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2000938211

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 2001132139

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017015844

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-4363

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000938211

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 53284/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000938211

Country of ref document: EP